TREATMENT READING
Plasma Cell Neoplasms (Including Multiple Myeloma)
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
98 sections
- Treatment Option Overview for Plasma Cell Neoplasms
- Asymptomatic Plasma Cell Neoplasms (Smoldering Multiple Myeloma)
- Symptomatic Plasma Cell Neoplasms
- Treatment of Amyloidosis Associated With Plasma Cell Neoplasms
- Treatment Options for Amyloidosis Associated With Plasma Cell Neoplasms
- Induction therapy
- Stem cell rescue
- Monoclonal antibody targeting of amyloid deposits
- Treatment of Monoclonal Gammopathy of Undetermined Significance
- Treatment Options for Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Watchful waiting
- Treatment of Waldenström Macroglobulinemia (Lymphoplasmacytic Lymphoma)
- Treatment of Isolated Plasmacytoma of Bone
- Treatment Options for Isolated Plasmacytoma of Bone
- Radiation therapy
- Chemotherapy
- Treatment of Extramedullary Plasmacytoma
- Treatment Options for Extramedullary Plasmacytoma
- Treatment of Multiple Myeloma
- Initial Evaluation
- Therapeutic Overview
- Indolent myeloma (smoldering multiple myeloma)
- Symptomatic myeloma
- Fit patients in good or well-controlled health
- Less-fit patients with significant comorbidities or advanced age (aged ≥80 years)
- High risk versus standard risk
- Measurable Residual Disease
- Induction Therapy
- Fit patients in good or well-controlled health
- Less-fit patients with significant comorbidities or advanced age (aged ≥80 years)
- Consolidation Therapy
- Autologous bone marrow or peripheral stem cell transplant
- Single autologous bone marrow or peripheral stem cell transplant
- Tandem autologous bone marrow or peripheral stem cell transplant followed by autologous or allogeneic transplant
- Allogeneic bone marrow or peripheral stem cell transplant
- Salvage autologous bone marrow or peripheral stem cell transplant after relapse from first transplant
- Maintenance Therapy
- Maintenance therapy (lenalidomide, ixazomib, and daratumumab alone or in combination)
- Proteasome inhibitor maintenance therapy
- Management and Prevention of Myeloma Bone Disease
- Zoledronate (bisphosphonate)
- Pamidronate (bisphosphonate)
- Denosumab (RANKL inhibitor)
- Radiation therapy for bone lesions
- Treatment of Relapsed or Refractory Multiple Myeloma
- Treatment Options for Relapsed or Refractory Multiple Myeloma
- Monoclonal antibodies
- Daratumumab
- Elotuzumab
- Isatuximab
- Proteasome inhibitors
- Bortezomib
- Carfilzomib
- Ixazomib
- CAR T-cell therapy
- Ciltacabtagene autoleucel
- Idecabtagene vicleucel (ide-cel)
- Bispecific antibody therapy
- Teclistamab
- Talquetamab
- Elranatamab
- Immunomodulatory agents
- Pomalidomide
- Lenalidomide
- Thalidomide
- BCMA-targeting antibody-drug conjugates
- Belantamab mafodotin
- Chemotherapy (cytotoxic agents)
- Selinexor
- Venetoclax
- BRAF/MEK inhibitors
- Corticosteroids
- Certain factors affect prognosis (chance of recovery) and treatment options.
- Plasma cell neoplasms may not respond to treatment or may come back after treatment.
- Treatment Option Overview
- Key Points
- There are different types of treatment for patients with plasma cell neoplasms.
- The following types of treatment are used:
- Chemotherapy
- Other drug therapy
- Targeted therapy
- High-dose chemotherapy with stem cell transplant
- Immunotherapy
- Radiation therapy
- Surgery
- Watchful waiting
- New types of treatment are being tested in clinical trials.
- New combinations of therapies
- Treatment for plasma cell neoplasms may cause side effects.
- Supportive care is given to lessen the problems caused by the disease or its treatment.
- Patients may want to think about taking part in a clinical trial.
- Patients can enter clinical trials before, during, or after starting their cancer treatment.
- Follow-up tests may be needed.
- Treatment of Monoclonal Gammopathy of Undetermined Significance
- Treatment of Isolated Plasmacytoma of Bone
- Treatment of Extramedullary Plasmacytoma
- Treatment of Multiple Myeloma
- Treatment of Relapsed or Refractory Multiple Myeloma
Treatment Option Overview for Plasma Cell Neoplasms
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
The major challenge in treating plasma cell neoplasms is separating the stable asymptomatic patients who do not require immediate treatment from patients with progressive symptomatic myeloma who may need to be treated immediately.[1-3] Monoclonal gammopathy of undetermined significance or smoldering myeloma must be distinguished from progressive myeloma.
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Asymptomatic Plasma Cell Neoplasms (Smoldering Multiple Myeloma)
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Asymptomatic patients with multiple myeloma who have no lytic bone lesions and normal renal function may be initially observed safely outside the context of a clinical trial.[1,4,5] Increasing anemia is the most reliable indicator of progression.[5] The following criteria represent the new definition for smoldering myeloma:[3]
Serum monoclonal protein immunoglobulin (Ig) G or IgA of at least 30 g/L or urinary monoclonal protein of at least 500 mg per 24 hours.
Clonal bone marrow plasma cells 10% to 60% (>60% represents overt myeloma).
Absence of amyloidosis or myeloma-defining events as follows:
Absence of amyloidosis or myeloma-defining events as follows:
Hypercalcemia greater than 1 mg/dL higher than reference range.
Creatinine greater than 2 mg/dL or creatinine clearance less than 40 mL/min.
Anemia with hemoglobin less than 10.0 g/dL.
Bone lesions (one or more) on skeletal radiography, computed tomography (CT) or positron emission tomography (PET)-CT.
Clonal plasma cell percentage in marrow at 60% or more.
Involved:uninvolved serum free light chain (FLC) ratio of 100 or more.
More than one focal lesion of at least 5 mm on magnetic resonance imaging (MRI) of the spine.
The International Myeloma Working Group (IMWG) 2/20/20 rule measures four adverse risk factors for patients with smoldering myeloma. The presence of three or four of the following adverse factors predicts a greater than 50% chance of progression to myeloma within 2 years:[6]
Sources: 6
Serum monoclonal (or myeloma) protein (M protein) greater than 2 g/dL.
Involved:uninvolved serum FLC ratio of more than 20.
Bone marrow plasma cell infiltration of more than 20%.
t(4;14), t(14;16), 1q gain, or del13q/monosomy 13 chromosomal abnormality.
Clinical trials evaluating smoldering myeloma need to exclude patients at high risk of progression to myeloma because those patients should consider induction therapy for symptomatic patients. For more information, see the Symptomatic Plasma Cell Neoplasms section.
Sources: Symptomatic Plasma Cell Neoplasms
In a prospective randomized trial of 390 patients with smoldering myeloma, patients were eligible if the marrow plasmacytosis was 10% to 49% and one of the following criteria was met: These patients received daratumumab (the anti-CD38 monoclonal antibody) or no therapy.[7]Summary: This trial did not show a significant improvement in OS or quality of life. However, the significant and clinically relevant delay in progression may particularly benefit older, less fit patients with myeloma. Early use of daratumumab did not result in a shortened OS after the subsequent initiation of full-dose induction therapy.
Sources: 7
In a prospective randomized trial of 390 patients with smoldering myeloma, patients were eligible if the marrow plasmacytosis was 10% to 49% and one of the following criteria was met: These patients received daratumumab (the anti-CD38 monoclonal antibody) or no therapy.[7]Summary: This trial did not show a significant improvement in OS or quality of life. However, the significant and clinically relevant delay in progression may particularly benefit older, less fit patients with myeloma. Early use of daratumumab did not result in a shortened OS after the subsequent initiation of full-dose induction therapy.
M protein of at least 3 g/dL.
Immunoparesis of two Ig classes.
Involved:uninvolved serum FLC ratio of 8 to 99.
IgA monoclonal protein.
Marrow plasmacytosis of 50% to 59%.
With a median follow-up of 65.2 months, the 5-year progression-free survival rate was 63.1% for patients in the daratumumab arm and 40.8% for patients in the watchful waiting arm (hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.36–0.67; P < .0001).[7][Level of evidence B1]
Sources: 7 · Level of evidence B1
The median time to progression was 44.1 months for patients in the daratumumab arm and 17.8 months for patients in the watchful waiting arm (HR, 0.51; 95% CI, 0.40–0.66; P < .0001).
The 5-year overall survival (OS) rate was 93% for patients in the daratumumab arm and 86% for patients in the watchful waiting arm (HR, 0.52; 95% CI, 0.27–0.98).
Three quality-of-life assessments showed no difference between the arms.
Symptomatic Plasma Cell Neoplasms
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Patients with symptomatic advanced disease require treatment.
Treatment most often is directed at reducing the tumor cell burden and reversing any complications of disease, such as renal failure, infection, hyperviscosity, or hypercalcemia, with appropriate medical management. The IMWG has published new criteria for identifying patients with active myeloma who require therapy:[3]
Sources: 3
Amyloidosis.
Hypercalcemia greater than 1 mg/dL higher than reference range.
Creatinine greater than 2 mg/dL or creatinine clearance less than 40 mL/min. Myeloma can cause renal dysfunction via hypercalcemia, amyloidosis, or light chain deposition disease.[8]
Sources: 8
Anemia with hemoglobin less than 10.0 g/dL.
Bone lesions (one or more) on skeletal radiography, whole-body MRI or spine and pelvis MRI, or PET-CT scans.[9]
Sources: 9
Clonal plasma cell percentage in marrow at 60% or more.
Involved:uninvolved serum FLC ratio of 100 or more.
More than one focal lesion of at least 5 mm on skeletal bone survey, or if negative, total-body MRI, or MRI of the spine and pelvis, or PET-CT scan.
Response criteria have been developed for patients on clinical trials by the IMWG.[10] A very good partial response (VGPR) is defined as a reduction of 90% or more in the serum monoclonal protein and a 24-hour urine monoclonal protein of less than 100 mg. Although not incorporated in the IMWG criteria, many trials report near complete response when patients have less than 5% bone marrow plasma cells and unmeasurable serum monoclonal proteins but still have positive serum and/or urine immunofixation. Note that these near complete response patients are incorporated into the VGPR group by the IMWG. Patients who achieve a complete response by IMWG criteria (with a negative immunofixation along with the clear marrow and unmeasurable serum monoclonal proteins) are often said to have attained a stringent complete response if their free kappa/lambda light–chain levels and ratio return to reference ranges. The clinical utility of these various categories must be validated in clinical trials.
Sources: 10
Therapy options for patients with symptomatic myeloma include:
Induction therapies.
Consolidation therapies, which are less applicable for patients of advanced age.
Maintenance therapies.
Supportive care, such as bisphosphonates. For more information, see the Pharmacological Therapies for Pain Control section in Cancer Pain.
Infection prevention, which includes vaccination, antimicrobial prophylaxis, and immunoglobulin replacement (in a small subset of patients), per consensus guidelines from the IMWG.[11]
Sources: 11
Treatment of Amyloidosis Associated With Plasma Cell Neoplasms
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Treatment Options for Amyloidosis Associated With Plasma Cell Neoplasms
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Treatment depends on assessing the extent of systemic damage from the amyloidosis and the underlying plasma cell dyscrasia.[1,2] A rising and elevated level of N-terminal pro-brain natriuretic peptide (NT-proBNP) may predict impending cardiac failure in cases of cardiac amyloidosis, and early treatment should be considered for these patients.[3]
Treatment options for amyloidosis associated with plasma cell neoplasms include:
Induction therapy.
Sources: Induction therapy
Stem cell rescue.
Sources: Stem cell rescue
Monoclonal antibody targeting of amyloid deposits (under clinical evaluation).
Induction therapy
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
As is true for all plasma cell dyscrasias, responses have been reported for patients treated with all the same regimens active in multiple myeloma.[4-12] Lower doses of lenalidomide or pomalidomide must be used in patients with renal dysfunction.[13] Patients with amyloidosis respond to treatment with daratumumab, with or without other active agents. Daratumumab is usually combined with other agents used for myeloma.[14-20] Rapid responses to induction therapy may result in improvement of renal or cardiac function.[21,22]
Evidence (chemotherapy):
A prospective trial (NCT03201965) included 388 previously untreated patients with immunoglobulin light-chain amyloidosis (excluding symptomatic myeloma). Patients were randomly assigned to receive bortezomib, cyclophosphamide, and dexamethasone with or without subcutaneous daratumumab.[23]Daratumumab combined with bortezomib, cyclophosphamide, and dexamethasone is considered a standard regimen for previously untreated patients who are eligible to receive this regimen. When using daratumumab induction therapy, the fluorescence in situ hybridization–detected cytogenetic abnormality of t(11;14) no longer confers an adverse prognostic impact. However, the presence of 1q gain continues to be associated with a lower response rate and hematologic event-free survival during treatment of amyloid light chain amyloidosis.[24]
Sources: NCT03201965 · 23 · 24
A prospective trial (NCT03201965) included 388 previously untreated patients with immunoglobulin light-chain amyloidosis (excluding symptomatic myeloma). Patients were randomly assigned to receive bortezomib, cyclophosphamide, and dexamethasone with or without subcutaneous daratumumab.[23]Daratumumab combined with bortezomib, cyclophosphamide, and dexamethasone is considered a standard regimen for previously untreated patients who are eligible to receive this regimen. When using daratumumab induction therapy, the fluorescence in situ hybridization–detected cytogenetic abnormality of t(11;14) no longer confers an adverse prognostic impact. However, the presence of 1q gain continues to be associated with a lower response rate and hematologic event-free survival during treatment of amyloid light chain amyloidosis.[24]
With a median follow-up of 11.4 months, the hematologic complete response rate was 53% for patients in the daratumumab group and 18.1% for patients in the control group (relative risk, 2.9; 95% confidence interval [CI], 2.1–4.1; P < .001). A landmark analysis at 6 months was also performed.[23][Level of evidence B3]
Sources: 23 · Level of evidence B3
Survival free from organ deterioration, hematologic progression, or death favored the daratumumab arm (hazard ratio, 0.58; 95% CI, 0.36–0.93; P = .02).
The cardiac and renal responses were doubled for patients in the daratumumab group, but no statistical analysis was provided.
Stem cell rescue
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
A prospective randomized study of 100 patients with immunoglobulin light-chain amyloidosis compared melphalan plus high-dose dexamethasone with high-dose melphalan plus autologous stem cell rescue.[25] After a median follow-up of 3 years, median overall survival (OS) favored the nontransplant arm (56.9 months vs. 22.2 months; P = .04).[25][Level of evidence A1] The 24% transplant-related mortality in this series and others reflects the difficulties involved with high-dose chemotherapy in older patients with organ dysfunction.[25-30] Between 2007 and 2012, the International Blood and Marrow Transplant Research Program identified 800 patients with amyloidosis who underwent autologous stem cell transplant (SCT); the 5-year OS rate was 77% and the transplant-related mortality rate was 5%, suggesting better selection of patients for transplant.[31][Level of evidence C1] Similarly, in a retrospective review of 672 consecutive patients with amyloidosis who underwent autologous SCT over 20 years, the treatment-related mortality rate declined to 2.4% between 2010 and 2016, compared with rates of 8.6% between 2003 and 2009 and 14.5% between 1996 and 2002.[32][Level of evidence C2] A randomized trial confirming the benefit of autologous SCT is not anticipated.[3,33]
Sources: 25 · 25 · Level of evidence A1 · 25 · 30 · 31 · Level of evidence C1 · 32 · Level of evidence C2 · 3 · 33
An anecdotal series described full-intensity and reduced-intensity allogeneic SCT.[34]
Sources: 34
Monoclonal antibody targeting of amyloid deposits
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
The monoclonal antibody anselamimab binds to immunoglobulin-associated amyloid in an effort to promote phagocytosis and clearance of the amyloid deposits.
In a phase I study (NCT02245867), 27 patients with deep hematologic responses to myeloma therapy, but persistent organ involvement, received anselamimab.[35]This treatment is not approved by the U.S. Food and Drug Administration and is under clinical evaluation.[35][Level of evidence C3]
Sources: 35 · 35 · Level of evidence C3
In a phase I study (NCT02245867), 27 patients with deep hematologic responses to myeloma therapy, but persistent organ involvement, received anselamimab.[35]This treatment is not approved by the U.S. Food and Drug Administration and is under clinical evaluation.[35][Level of evidence C3]
Fifteen of 24 patients (63%) manifested cardiac, renal, hepatic, gastrointestinal, or soft tissue response by serum biomarkers (such as NT-proBNP), renal function, cardiac function, or imaging studies.
Treatment of Monoclonal Gammopathy of Undetermined Significance
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Treatment Options for Monoclonal Gammopathy of Undetermined Significance (MGUS)
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Treatment options for MGUS include:
Watchful waiting.
Sources: Watchful waiting
Watchful waiting
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Multiple myeloma, other plasma cell dyscrasia, or lymphoma will develop in 12% of patients by 10 years, 25% of patients by 20 years, and 30% of patients by 25 years.
All patients with MGUS are generally observed to detect increases in monoclonal (M) protein levels and development of a plasma cell dyscrasia. Higher levels of initial M protein levels may correlate with increased risk of progression to multiple myeloma.[1,2] In a large retrospective report, the risk of progression at 20 years was 14% for an initial M protein level of 0.5 g/dL or less, 25% for a level of 1.5 g/dL, 41% for a level of 2.0 g/dL, 49% for a level of 2.5 g/dL, and 64% for a level of 3.0 g/dL.[1]
Treatment is delayed until the disease progresses to the stage that symptoms or signs appear.
Patients with MGUS or smoldering myeloma do not respond more frequently, achieve longer remissions, or have improved survival if chemotherapy is started early while they are still asymptomatic as opposed to waiting for progression before treatment is initiated.[3-6] Newer therapies have not been proven to prevent or delay the progression of MGUS to a plasma cell dyscrasia.[2]
Treatment of Waldenström Macroglobulinemia (Lymphoplasmacytic Lymphoma)
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
For more information, see the Lymphoplasmacytic Lymphoma (Waldenström Macroglobulinemia) section in Indolent B-Cell Non-Hodgkin Lymphoma Treatment.
Sources: Lymphoplasmacytic Lymphoma (Waldenström Macroglobulinemia)
Treatment of Isolated Plasmacytoma of Bone
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Treatment Options for Isolated Plasmacytoma of Bone
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Treatment options for isolated plasmacytoma of bone include:
Radiation therapy to the lesion.
Sources: Radiation therapy
Chemotherapy (if monoclonal [or myeloma] protein [M protein] increases and other evidence of symptomatic multiple myeloma occurs).
Sources: Chemotherapy
Radiation therapy
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
About 25% of patients have serum and/or urine M protein present. Generally, this disappears after adequate radiation therapy to the lytic lesion.
The survival rate of patients with isolated plasmacytoma of bone treated with radiation therapy to the lesion is greater than 50% at 10 years, which is more favorable than the survival rate of patients with disseminated multiple myeloma.[1]
Sources: 1
Chemotherapy
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Most patients eventually develop disseminated disease and require chemotherapy. Almost 50% of patients do so within 2 years of diagnosis.[2,3] However, patients with serum paraprotein or Bence Jones protein, who have complete disappearance of these proteins after radiation therapy, may remain free of disease for prolonged periods.[2,4] Patients with a negative flow cytometry on bone marrow examination for plasma cell infiltration are also unlikely to relapse.[5] Patients with progression to multiple myeloma often have good responses to chemotherapy, with a median survival of 63 months after progression.[2,4]
Treatment of Extramedullary Plasmacytoma
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Treatment Options for Extramedullary Plasmacytoma
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Treatment options for extramedullary plasmacytoma include:
Radiation therapy to the isolated lesion with fields that cover the regional lymph nodes, if possible.[1,2]
In some cases, surgical resection may be considered, but it is usually followed by radiation therapy.[2]
Sources: 2
If the presence of monoclonal (or myeloma) protein (M protein) persists or reappears, the patient may need further radiation therapy. In some patients, the plasmacytoma may shrink, but not disappear, and the M protein persists. Close follow-up is generally warranted for these patients. Surgery is often performed if the plasmacytoma is in a site where it can be removed easily (e.g., in the tonsil); the M protein may disappear from the blood or urine. In other cases, persistence or an increasing M protein may herald progression to multiple myeloma.
Chemotherapy is required if the disease progresses and causes symptoms.
Patients with isolated plasma cell tumors of soft tissues, most commonly occurring in the tonsils, nasopharynx, or paranasal sinuses, may need to have skeletal x-rays and bone marrow biopsy (both of which are most often negative) and evaluation for M protein in serum and urine.[1-4]
About 25% of patients have serum and/or urine M protein; this frequently disappears after adequate radiation.
Treatment of Multiple Myeloma
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Initial Evaluation
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
The initial approach to the patient is to evaluate the following parameters:
Detection and quantification of a monoclonal (or myeloma) protein (M protein) in the serum or urine, and possible immunoparesis (suppression of the other uninvolved immunoglobulins [Ig]).[1]
Sources: 1
Detection of more than 10% of plasma cells on a bone marrow examination, along with flow cytometry, cytogenetics, and fluorescence in situ hybridization testing.
Detection of lytic bone lesions or generalized osteoporosis in skeletal x-rays, or whole-body or spinal and pelvic magnetic resonance imaging (MRI) scans, or focal bone lesions on positron emission tomography-computed tomography (CT) scan.[2,3]
Presence of soft tissue plasmacytomas.
Serum albumin and beta-2-microglobulin levels.
Detection of free kappa and free lambda serum Ig light chain, with calculation of the serum free light chain ratio.[1,4]
Presence of hypercalcemia.
Detection of renal dysfunction attributable to the plasma cell dyscrasia (induced by gammopathy or amyloidosis).
Presence of anemia.
Presence of circulating plasma cells.
Presence of hyperviscosity. Asymptomatic patients usually respond to myeloma therapy; plasma exchange is indicated with hemorrhagic or central nervous system manifestations.[5]
Sources: 5
Treatment selection is influenced by the age and general health of the patient, previous therapy, and the presence of disease complications.[6]
Sources: 6
Therapeutic Overview
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Despite the introduction of many new therapeutic agents over the past two decades, there is still no confirmed curative approach.
Indolent myeloma (smoldering multiple myeloma)
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
For information on watchful waiting versus immediate therapy for patients with asymptomatic smoldering myeloma, see the Asymptomatic Plasma Cell Neoplasms (Smoldering Multiple Myeloma) section.
Sources: Asymptomatic Plasma Cell Neoplasms (Smoldering Multiple Myeloma)
Symptomatic myeloma
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Newly diagnosed patients who require therapy fall into two categories: (1) patients in good or well-controlled health (previously referred to as the fit, transplant-eligible patient) or (2) the less-fit patient with significant comorbidities or advanced age (previously referred to as not transplant eligible). Comorbidities and performance status are important determinants to help decide about fitness of patients at all ages, especially those between the ages of 70 years and 80 years. Nomograms exist for geriatric patients to define life expectancy independent of the myeloma diagnosis.[7] Age, organ dysfunction, and risk of cardiovascular and thrombotic complications influence the choice of induction therapies. These factors are also important when considering consolidation therapies, such as chimeric antigen receptor T-cell therapy, bispecific antibody therapy, and autologous stem cell transplant (SCT) consolidation. Most patients also receive a bisphosphonate or RANKL inhibitor to prevent skeletal-related complications.[8,9]
The International Myeloma Working Group has issued guidance for the diagnosis and management of patients with renal impairment.[10]
Sources: 10
Fit patients in good or well-controlled health
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Patients in good or well-controlled health may receive induction chemotherapy with a four-drug (quadruplet) or three-drug (triplet) approach that includes bortezomib in the absence of a clinical trial. The most commonly used regimens include:
D-CVRd: daratumumab + cyclophosphamide + bortezomib + lenalidomide + dexamethasone.
CyBorD: cyclophosphamide + bortezomib + dexamethasone.[19,20] This regimen is preferred in the presence of significant renal dysfunction (creatinine clearance less than 45 cc/min). If the renal function recovers rapidly, some clinicians switch to VRd.
After 4 to 8 months of therapy, patients with disease response may undergo autologous SCT consolidation.[16,21] The previously standard autologous SCT consolidation has been questioned because a large, prospective, randomized trial failed to demonstrate an overall survival (OS) benefit.[22] Maintenance therapy is then implemented until the time of relapse.[23-25] At relapse, subsequent therapies are given sequentially by using previously successful drugs (if the interval of time since previous exposure is >1 year) or newer drugs not previously tried.
Less-fit patients with significant comorbidities or advanced age (aged ≥80 years)
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
The less-fit patient may receive induction chemotherapy with a triplet or quadruplet regimen (as described for the patient in good or well-controlled health, but with dosage adjustments) including the CD38-directed monoclonal antibodies daratumumab or isatuximab, or with a doublet regimen including daratumumab or isatuximab, which might be better tolerated.[26] Therapy is continued until maximal response, and then maintenance therapy is given until relapse.[27] At relapse, subsequent therapies are given sequentially (as described for the patient in good or well-controlled health).
High risk versus standard risk
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Patients with newly diagnosed or relapsing myeloma can be identified as having standard-risk or high-risk disease. This determination is made based on cytogenetics, genetic aberrations detected by fluorescence in situ hybridization, and possibly the genetic expression profile analyses that are in the process of standardization.[28] Plasma cell leukemia at presentation, or as a leukemic evolution of refractory myeloma, is a particularly high-risk, poor-prognosis entity.[29-33] Plasma cell leukemia with an ultra-high poor prognosis is defined by the presence of more than 2% circulating tumor plasma cells by flow cytometry.[34] Higher-risk patients are candidates for clinical trials using newer agents upfront or newer combination therapies currently used for relapsed disease at the discretion of the clinician.[35-37] Beyond induction therapy, high-risk disease can warrant more aggressive strategies, such as tandem transplant or consideration of allogeneic SCT. More intensive maintenance therapies may also be given for high-risk disease; instead of using lenalidomide alone, lenalidomide plus bortezomib has been chosen based on prior trials using thalidomide.[38] These more aggressive strategies have been implemented because of poor responsiveness to standard regimens and the worse prognosis of high-risk patients. Ultimately, prospective randomized trials are needed to establish improved outcomes with these newer approaches for high-risk patients.
Measurable Residual Disease
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
The assessment of measurable residual disease (MRD) in the bone marrow is mandatory for the assessment of efficacy in clinical trials.[39-42] Does MRD testing outside of the trial setting yield meaningful clinical improvement in patient outcomes by informing selection or duration of therapy? Achievement of MRD negativity after induction therapy (with or without consolidation therapy) is associated with improved progression-free survival (PFS) and improved OS.[43-52] While MRD negativity may be useful for the design of clinical trials, there are no data suggesting that this interim marker improves outcomes by altering subsequent therapy. Similarly, there are no data to suggest that sustained MRD negativity can allow deintensification or discontinuation of maintenance therapy.[53,54] Using peripheral blood to assess for MRD appears feasible with next-generation flow and mass spectroscopy. This approach is less-invasive than using bone marrow.[55]
Induction Therapy
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Patients with myeloma who are symptomatic or require therapy because of progression or adverse laboratory findings require induction therapy. Ideally, induction therapy should reduce tumor burden, provide symptomatic relief, and prevent further end-organ damage.
Fit patients in good or well-controlled health
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Two prospective randomized trials evaluated induction therapy with the D-VRd regimen (which includes daratumumab, an anti-CD38 monoclonal antibody) in fit patients in good or well-controlled health. Another prospective randomized trial evaluated I-VRd (which includes isatuximab, another anti-CD38 monoclonal antibody) as an alternative induction therapy.
A prospective trial included 709 transplant-eligible patients with newly diagnosed myeloma. Patients were randomly assigned to receive either D-VRd or VRd. All patients received an autologous SCT and subsequent lenalidomide maintenance therapy.[56]
Sources: 56
A prospective trial included 709 transplant-eligible patients with newly diagnosed myeloma. Patients were randomly assigned to receive either D-VRd or VRd. All patients received an autologous SCT and subsequent lenalidomide maintenance therapy.[56]
With a median follow-up of 47.5 months, the 4-year PFS rate was 84.3% in the D-VRd group and 67.7% in the VRd group (hazard ratio [HR], 0.42; 95% confidence interval [CI], 0.30–0.59; P < .001).[56][Level of evidence B1]
Sources: 56 · Level of evidence B1
The complete response rate was 87.9% in the D-VRd group and 70.1% in the VRd group (P < .001). The percentage of patients who achieved MRD-negative status favored D-VRd (75.2% vs. 47.5%; P < .001).
The most common grade 3 or 4 adverse event was neutropenia, which occurred in 62% of patients who received D-VRd and 51% of patients who received VRd.
The phase II GRIFFIN trial (NCT02874742) enrolled 207 patients with newly diagnosed transplant-eligible multiple myeloma. Patients were randomly assigned to receive induction therapy with either D-VRd or VRd. Patients then received an autologous SCT, two more cycles of the induction regimen, and 2 years of maintenance therapy with Dara-R (daratumumab and lenalidomide) or lenalidomide alone depending on the original randomization.[57]
The phase II GRIFFIN trial (NCT02874742) enrolled 207 patients with newly diagnosed transplant-eligible multiple myeloma. Patients were randomly assigned to receive induction therapy with either D-VRd or VRd. Patients then received an autologous SCT, two more cycles of the induction regimen, and 2 years of maintenance therapy with Dara-R (daratumumab and lenalidomide) or lenalidomide alone depending on the original randomization.[57]
With a median follow-up of 49.6 months, the percentage of patients with a stringent complete response was 67% in the D-VRd group and 48% in the VRd group (odds ratio [OR], 2.18; 95% CI, 1.22–3.89; P = .0079).[57][Level of evidence B3]
Sources: 57 · Level of evidence B3
The 4-year PFS rate was 87.2% in the D-VRd group and 70.0% in the VRd group (HR, 0.45; 95% CI, 0.21–0.95; P = .032).[57][Level of evidence B3]
Sources: 57 · Level of evidence B3
The median OS was not reached in either group (HR, 0.90; 95% CI, 0.31–2.56; P = .84).
A Markov model using MRD status to predict PFS suggested improved quality of life and lower cost over 10 years with the use of daratumumab in the first-line setting.[58]
Sources: 58
A prospective trial, reported in abstract form, included 662 transplant-eligible patients with newly diagnosed myeloma. Patients were randomly assigned to receive either I-VRd or VRd. All patients received an autologous SCT and subsequent lenalidomide maintenance therapy.[13]
Sources: 13
A prospective trial, reported in abstract form, included 662 transplant-eligible patients with newly diagnosed myeloma. Patients were randomly assigned to receive either I-VRd or VRd. All patients received an autologous SCT and subsequent lenalidomide maintenance therapy.[13]
With a median follow-up of 47.0 months, the 3-year PFS rate was 83% in the I-VRd group and 75% in the VRd group (HR, 0.70; 95% CI, 0.52–0.94; P = .02).[13][Level of evidence B1]
Sources: 13 · Level of evidence B1
Isatuximab is given intravenously (IV), unlike daratumumab, which is given subcutaneously.
A more intensive regimen of induction therapy, consolidation therapy, and maintenance therapy was investigated in patients with high-risk cytogenetic abnormalities.
In the multicenter phase II OPTIMUM trial (NCT03188172), 412 newly diagnosed patients were screened to identify 103 patients with ultra–high-risk (UHR) myeloma or plasma cell leukemia.[59] UHR myeloma was defined by the presence of at least two specified genetic risk markers (t(4;14), t(14;16), t(14;20), del (1p), 1q gain, and del 17p)) and/or SKY92 gene expression risk signature. All patients were treated with D-CVRd induction for six cycles (or until maximum response), autologous SCT consolidation, and D-VRd consolidation followed by Dara-R maintenance.[60]
In the multicenter phase II OPTIMUM trial (NCT03188172), 412 newly diagnosed patients were screened to identify 103 patients with ultra–high-risk (UHR) myeloma or plasma cell leukemia.[59] UHR myeloma was defined by the presence of at least two specified genetic risk markers (t(4;14), t(14;16), t(14;20), del (1p), 1q gain, and del 17p)) and/or SKY92 gene expression risk signature. All patients were treated with D-CVRd induction for six cycles (or until maximum response), autologous SCT consolidation, and D-VRd consolidation followed by Dara-R maintenance.[60]
With a median follow-up of 41.2 months, the 30-month PFS rate was 77% (95% CI, 69%–81%) for patients who received the study treatment versus 40% (95% CI, 31%–49%) for an historical control group who received KCRD (carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone).[59][Level of evidence C2] The 30-month OS rate was 84% (95% CI, 76%–91%) for patients who received the OPTIMUM regimen and 74% (95% CI, 66%–82%) for the historical control KCRD regimen.[59][Level of evidence C1]
Sources: 59 · Level of evidence C2 · 59 · Level of evidence C1
The study design did not prove that D-CVRd is the preferred regimen for patients with UHR myeloma, but it is a feasible regimen for further randomized trials in this patient population.
In transplant-eligible patients, alkylators such as melphalan are avoided upfront to prevent stem cell toxicity with subsequent risks for cytopenias, secondary malignancies, or poor stem cell harvesting.[61] Bortezomib is given subcutaneously, which helps to avoid the neuropathies that were much more severe with IV administration.[62-64] Bortezomib is also preferred for patients with renal impairment.[65] Patients receiving a bortezomib-containing regimen need prophylaxis for herpes zoster (usually with valacyclovir or acyclovir). Lenalidomide is given orally and can cause an increased risk of deep venous thrombosis (DVT) or pulmonary embolism, requiring additional prophylactic medication.[66,67] Because lenalidomide is metabolized erratically in patients with renal failure, clinicians may choose the CyBorD regimen,[19,20] but this selection is empiric and not based on randomized trial results. For patients without extra risk factors for DVT, aspirin (81 mg daily) suffices, but stronger anticoagulants should be considered for patients with multiple risk factors who receive lenalidomide (or other similar immunomodulating agents such as pomalidomide or thalidomide). Lower doses of lenalidomide must be used for patients with renal dysfunction.[68]
Less-fit patients with significant comorbidities or advanced age (aged ≥80 years)
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Triplet or quadruplet therapies such as VRd and CyBorD with daratumumab or isatuximab can be used in patients with adequate fitness and minimal comorbidities. When triplets are deemed too difficult, doublets with Vd (bortezomib plus dexamethasone) or Rd (lenalidomide plus dexamethasone) can be used, or even a triplet such as VMP (bortezomib, melphalan, and prednisone).[15,26] Therapeutic options have changed with the advent of daratumumab and isatuximab, the CD38-directed monoclonal antibodies.
A prospective randomized trial, reported in abstract form, included 395 patients with newly diagnosed myeloma who were aged 70 years or older or ineligible for autologous SCT with medical comorbidities. Patients received D-VRd or VRd.[69]
Sources: 69
A prospective randomized trial, reported in abstract form, included 395 patients with newly diagnosed myeloma who were aged 70 years or older or ineligible for autologous SCT with medical comorbidities. Patients received D-VRd or VRd.[69]
With a median follow-up of 58.7 months, the 2-year MRD negativity (10-6) was 32.0% for patients who received D-VRd and 15.7% for patients who received VRd (HR, 0.40; 95% CI, 0.24–0.64; P = .001).[69][Level of evidence B3]
Sources: 69 · Level of evidence B3
A prospective randomized trial (NCT03319667) was conducted in 446 patients with newly diagnosed myeloma who were ineligible for transplant. Patients were randomly assigned in a 3:2 ratio to receive either I-VRd or VRd alone.[14]
Sources: NCT03319667 · 14
A prospective randomized trial (NCT03319667) was conducted in 446 patients with newly diagnosed myeloma who were ineligible for transplant. Patients were randomly assigned in a 3:2 ratio to receive either I-VRd or VRd alone.[14]
With a median follow-up of 59.7 months, the 5-year PFS rate was 63.2% for patients who received I-VRd versus 45.2% for patients who received VRd alone (HR, 0.60; 98.5% CI, 0.41–0.88; P < .001).[14][Level of evidence B1]
Sources: 14 · Level of evidence B1
Isatuximab is given IV, unlike daratumumab, which is given subcutaneously (with significantly less side effects than the IV formulation).
Serious adverse events were similar in the two groups.
In a prospective randomized trial (NCT02252172) of 737 patients with newly diagnosed myeloma who were ineligible for transplant, daratumumab plus lenalidomide and dexamethasone was compared with Rd alone.[70]
Sources: NCT02252172 · 70
In a prospective randomized trial (NCT02252172) of 737 patients with newly diagnosed myeloma who were ineligible for transplant, daratumumab plus lenalidomide and dexamethasone was compared with Rd alone.[70]
With a median follow-up of 56.2 months, the 60-month OS rate was 66.3% (95% CI, 60.8%–71.3%) for patients who received daratumumab and 53.1% (95% CI, 47.2%–58.6%) for patients who received Rd alone (HR, 0.68; 95% CI, 0.53–0.86; P = .0013).[70][Level of evidence A1]
Sources: 70 · Level of evidence A1
With a median follow-up of 56.2 months, the 60-month PFS rate was 52.5% for patients who received daratumumab (95% CI, 46.7%−58.0%) and 28.7% for patients who received Rd alone (95% CI, 23.1%−34.6%) (HR, 0.53; 95% CI, 0.43−0.66; P < .0001).[70]
Sources: 70
Results for the percentage of patients falling below the threshold for MRD (<1 tumor cell per 105 white cells) favored the daratumumab combination, 24.2% versus 7.3% (P < .001).
The daratumumab combination resulted in significant and sustained reductions of pain scores and improved quality of life in the EuroQOL 5-dimensional descriptive visual system.[71][Level of evidence A3]
Sources: 71 · Level of evidence A3
In a prospective randomized trial of 706 patients with newly diagnosed myeloma who were ineligible for transplant, daratumumab plus VMP was compared with VMP alone.[72]Immunological reaction to the initial dose of daratumumab can be modulated by splitting the first infusion over 2 days or using the subcutaneous version (this dosing schedule is not approved by the U.S. Food and Drug Administration).
Sources: 72
In a prospective randomized trial of 706 patients with newly diagnosed myeloma who were ineligible for transplant, daratumumab plus VMP was compared with VMP alone.[72]Immunological reaction to the initial dose of daratumumab can be modulated by splitting the first infusion over 2 days or using the subcutaneous version (this dosing schedule is not approved by the U.S. Food and Drug Administration).
With a median follow-up of 40.1 months, the 3-year OS rate favored the daratumumab combination group at 78% (95% CI, 73.2%−83.0%) versus 67.9% in the VMP-alone group (95% CI, 62.6%−72.6%) (HR, 0.60; 95% CI, 0.46−0.80; P = .003).[72][Level of evidence A1]
Sources: 72 · Level of evidence A1
With a median follow-up of 40.1 months, the 3-year PFS rate favored the daratumumab combination group at 50.7% (95% CI, 45.1%−55.9%) versus 18.5% in the VMP-alone group (95% CI, 14.4%−23.1%) (HR, 0.42; 95% CI, 0.34−0.51; P < .0001).[72][Level of evidence B1]
Sources: 72 · Level of evidence B1
In the daratumumab combination group, 22.3% of patients were MRD negative (at a threshold of one tumor cell per 105 white cells); in the VMP-alone group, 6.2% of patients were MRD negative (P < .001).
In a prospective randomized trial (NCT04751877), 270 patients with newly diagnosed myeloma who were transplant ineligible and aged 65 to 79 years received either I-VRd or isatuximab plus Rd.[73]
Sources: NCT04751877 · 73
In a prospective randomized trial (NCT04751877), 270 patients with newly diagnosed myeloma who were transplant ineligible and aged 65 to 79 years received either I-VRd or isatuximab plus Rd.[73]
With a median follow-up of 23.5 months, the MRD negativity rates (at 10-5) at 18 months were 53% for the I-VRd group and 26% for the isatuximab-Rd group (OR, 3.16; 95% CI, 1.89–5.28; P < .0001).[73][Level of evidence B3]
Sources: 73 · Level of evidence B3
Isatuximab is given IV, unlike daratumumab, which is given subcutaneously (with significantly less side effects than the IV formulation).
Serious adverse events were similar in the two groups.
In a prospective randomized trial, 955 patients with newly diagnosed multiple myeloma who were ineligible for transplant received either carfilzomib plus melphalan and prednisone or VMP.[74]
Sources: 74
In a prospective randomized trial, 955 patients with newly diagnosed multiple myeloma who were ineligible for transplant received either carfilzomib plus melphalan and prednisone or VMP.[74]
With a median follow-up of 23 months, there was no difference in median PFS (22.3 vs. 22.1 months; HR, 0.91; 95% CI, 0.75−1.10; P = .159) or in median OS (HR, 1.1; 95% CI, 0.82−1.4).[74][Level of evidence A1]
Sources: 74 · Level of evidence A1
In a prospective trial, 1,087 patients with standard-risk or intermediate-risk myeloma who deferred transplant for induction therapy were randomly assigned to receive carfilzomib plus lenalidomide and dexamethasone or bortezomib plus lenalidomide and dexamethasone.[75]
Sources: 75
In a prospective trial, 1,087 patients with standard-risk or intermediate-risk myeloma who deferred transplant for induction therapy were randomly assigned to receive carfilzomib plus lenalidomide and dexamethasone or bortezomib plus lenalidomide and dexamethasone.[75]
With a median follow-up of 26 months, there was no difference in median PFS (34.6 vs. 34.4 months; HR, 1.04; 95% CI, 0.83−1.31; P = .742) or in median OS (HR, 0.98; 95% CI, 0.71−1.36; P = .923).[75][Level of evidence A1]
Sources: 75 · Level of evidence A1
Many other phase II and phase III trials, published in preliminary abstract form, show results similar to the trial that combined daratumumab with melphalan and prednisone, and used daratumumab with other triplets and doublets in both previously untreated and previously treated patients.[76,77] Further follow-up is required to establish OS benefits. Mature OS data are required to better assess the cost-effectiveness of daratumumab in the first-line setting.[78]
Consolidation Therapy
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Autologous bone marrow or peripheral stem cell transplant
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Evidence (autologous bone marrow or peripheral SCT):
The failure of conventional therapy to cure myeloma has led investigators to test the effectiveness of much higher doses of drugs such as melphalan. The development of techniques for harvesting hematopoietic stem cells, from marrow aspirates or the peripheral blood of the patient, and infusing these cells to promote hematopoietic recovery made it possible for investigators to test very large doses of chemotherapy.
Based on the experience of treating thousands of patients in this way, it is possible to draw a few conclusions:
The risk of early death caused by treatment-related toxic effects has been reduced to less than 3% in highly selected populations.[79]
Sources: 79
Extensive prior chemotherapy, especially with alkylating agents, compromises marrow hemopoiesis and may make the harvesting of adequate numbers of hematopoietic stem cells impossible.[61]
Sources: 61
Single autologous bone marrow or peripheral stem cell transplant
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Evidence (single autologous bone marrow or peripheral SCT):
While some prospective randomized trials showed improved survival for patients who received autologous peripheral stem cell or bone marrow transplant after induction chemotherapy compared with chemotherapy alone,[25,85-87][Level of evidence A1] other trials have not shown any survival advantage.[88-93][Level of evidence A1]
Sources: 25 · 85 · 87 · Level of evidence A1 · 88 · 93 · Level of evidence A1
In a prospective randomized trial (NCT01208662), 722 patients aged 65 years or younger with newly diagnosed multiple myeloma received either VRd for three cycles followed by autologous SCT consolidation and two more cycles of VRd or VRd alone for eight cycles. Both groups received maintenance lenalidomide given continuously in the absence of disease relapse or unacceptable side effects.[94] At relapse, patients who received VRd only (without autologous SCT) were re-induced and offered transplant if they were still responding.
Sources: NCT01208662 · 94
In a prospective randomized trial (NCT01208662), 722 patients aged 65 years or younger with newly diagnosed multiple myeloma received either VRd for three cycles followed by autologous SCT consolidation and two more cycles of VRd or VRd alone for eight cycles. Both groups received maintenance lenalidomide given continuously in the absence of disease relapse or unacceptable side effects.[94] At relapse, patients who received VRd only (without autologous SCT) were re-induced and offered transplant if they were still responding.
With a median follow-up of 76.0 months, the median PFS was shorter for patients in the nontransplant arm (42.0 months) than for patients in the transplant arm (67.5 months) (HR, 1.53; 95% CI, 1.23–1.91; P < .001).[94][Level of evidence B1]
Sources: 94 · Level of evidence B1
The 5-year OS rate was not significantly different: 79.2% for patients in the nontransplant arm versus 80.7% for patients in the transplant arm (HR, 1.10; 95% CI, 0.73–1.65; P > 0.99).
Rates of grade 3 or 4 hematologic adverse events were significantly higher in the transplant arm (41.9%) than in the nontransplant arm (26.1%) (P < .001). Acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) were only reported in the transplant arm (10 cases).
Only 28% of patients who received VRd originally received autologous SCT at any time after the end of study treatment.
Three meta-analyses of almost 3,000 patients showed no survival advantage.[22,95,96][Level of evidence A1]
Sources: 22 · 95 · 96 · Level of evidence A1
A meta-analysis was performed for all randomized clinical trials conducted between 2000 and 2021 that compared up-front autologous SCT with standard-dose therapy/consolidation. A total of 3,307 citations were screened: six trials were selected for PFS analysis and four trials were selected for OS analysis (2,959 patients).[97]
Sources: 97
A meta-analysis was performed for all randomized clinical trials conducted between 2000 and 2021 that compared up-front autologous SCT with standard-dose therapy/consolidation. A total of 3,307 citations were screened: six trials were selected for PFS analysis and four trials were selected for OS analysis (2,959 patients).[97]
With a median follow-up of 3.1 to 7.8 years, patients with high-risk cytogenetics (t(4;14), t(14;16), and/or del(17p)) had a significant OS benefit from autologous SCT versus standard-dose therapy (HR, 0.66; 95% CI, 0.45–0.97; P = .03).[97][Level of evidence A2] No survival benefit was seen for patients with standard-risk cytogenetics.
Sources: 97 · Level of evidence A2
Patients with high-risk disease (approximately 20% of the total) showed a significant PFS benefit from autologous SCT versus standard-dose therapy (HR, 0.52; 95% CI, 0.33–0.83). Patients with standard-risk disease also showed a PFS benefit from autologous SCT (HR, 0.65; 95% CI, 0.56–0.76).[97]
Sources: 97
Even the trials suggesting improved survival showed no signs of a slowing in the relapse rate or a plateau to suggest that any of these patients had been cured.[25,85-87,98] The role of autologous SCT has changed, from a mandated standard consolidation for those patients healthy enough to undergo it toward a therapeutic option, like any other, that offers approximately 2 years of increased PFS on average with defined toxicities. Incorporating, eliminating, delaying, or even replacing autologous SCT in the future (perhaps with chimeric antigen receptor T cells or bispecific antibodies) will be the subject of ongoing and upcoming clinical trials. Subgroups of patients may have a particular benefit from autologous SCT. Patients with a t(11;14) translocation may show differential benefit, as found in a retrospective review of 3,538 total patients in a dataset from the Center of International Blood and Marrow Transplant Research.[99] One meta-analysis of only four randomized clinical trials suggested an OS benefit for up-front autologous SCT in patients with high-risk cytogenetics.[97]
Tandem autologous bone marrow or peripheral stem cell transplant followed by autologous or allogeneic transplant
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Another approach to high-dose therapy has been the use of two sequential infusions of high-dose therapy with stem cell support (tandem transplants).[100-104]
Evidence (tandem autologous bone marrow or peripheral SCT):
A meta-analysis of six randomized clinical trials enrolling 1,803 patients compared single autologous hematopoietic cell transplant with tandem autologous hematopoietic cell transplant.
A meta-analysis of six randomized clinical trials enrolling 1,803 patients compared single autologous hematopoietic cell transplant with tandem autologous hematopoietic cell transplant.
There was no difference in OS (HR, 0.94; 95% CI, 0.77–1.14) or in event-free survival (EFS) (HR, 0.86; 95% CI, 0.70–1.05).[105][Level of evidence A2]
Sources: 105 · Level of evidence A2
A prospective randomized trial of 758 patients who completed induction therapy in less than 12 months compared autologous SCT plus lenalidomide maintenance, tandem autologous SCT, and autologous SCT plus VRd maintenance.[106]
Sources: 106
A prospective randomized trial of 758 patients who completed induction therapy in less than 12 months compared autologous SCT plus lenalidomide maintenance, tandem autologous SCT, and autologous SCT plus VRd maintenance.[106]
There was no difference in 38-month PFS (53.9%−58.5%) and OS (81.8%−85.4%) rates among these three randomized groups.[106][Level of evidence A1]
Sources: 106 · Level of evidence A1
Five different groups have compared single or tandem autologous transplants with one autologous transplant followed by a reduced-intensity conditioning allograft from a HLA-identical sibling; treatment assignment was based on the presence or absence of an HLA-identical sibling. The results have been discordant for survival in these nonrandomized trials.[107-110][Level of evidence C1]
Sources: 107 · 110 · Level of evidence C1
Six clinical trials compared the outcomes of patients receiving tandem autologous transplant with those of patients receiving a reduced-intensity allogeneic SCT after autologous transplant. Patients were assigned to the latter treatments based on the availability of an HLA-matched donor. Two meta-analyses of these data showed that although the complete remission rate was higher in patients undergoing reduced-intensity allogeneic SCT, OS was comparable because of an increased incidence of nonrelapse mortality with allogeneic transplant.[111,112][Level of evidence A1]
Sources: 111 · 112 · Level of evidence A1
A Cochrane review of 14 controlled studies found none of the trials helpful for contemporary treatment decisions regarding single versus tandem transplants.[113] None of the trials used bortezomib or lenalidomide, and the sharp decrease in compliance with a second transplant complicated sample-size calculations for sufficient statistical power.
Sources: 113
Allogeneic bone marrow or peripheral stem cell transplant
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Evidence (allogeneic bone marrow or peripheral SCT):
Many patients are not young enough or healthy enough to undergo these intensive approaches. A definite graft-versus-myeloma effect has been demonstrated, including regression of myeloma relapses after the infusion of donor lymphocytes.[114]
Sources: 114
Favorable prognostic features included:
Low tumor burden.
Responsive disease before transplant.
Application of transplant after first-line therapy.
Myeloablative allogeneic SCT has significant toxic effects (15%–40% mortality), but the possibility of a potent and possibly curative graft-versus-myeloma effect in a minority of patients may offset the high transplant-related mortality.[114-116] In one anecdotal series of 60 patients who underwent allogeneic SCT, six of the patients relapsed between 6 and 12 years, suggesting that late relapses still occur with this type of consolidation.[117]
The lower transplant-related mortality from nonmyeloablative approaches has been accompanied by a greater risk of relapse.[116] Since the introduction of lenalidomide and bortezomib, a trial exploring donor versus no donor comparison of autologous SCT versus autologous SCT and nonmyeloablative allogeneic SCT in 260 untreated patients showed no difference in PFS or OS.[118][Level of evidence C1] This result contrasted with two older trials (before introduction of lenalidomide and bortezomib), which suggested improvement of PFS and OS with a sibling donor.[109,119][Level of evidence C1]
Sources: 116 · 118 · Level of evidence C1 · 109 · 119 · Level of evidence C1
Six clinical trials compared the outcomes of patients receiving tandem autologous transplant with those of patients receiving a reduced-intensity autologous SCT after autologous transplant. Patients were assigned to the latter treatments based on the availability of an HLA-matched donor. Two meta-analyses of these data showed that although the complete remission rate was higher in patients undergoing reduced-intensity autologous SCT, OS was comparable because of an increased incidence of nonrelapse mortality with allogeneic transplant.[111,112][Level of evidence A1] Anecdotal long-term survivals have been reported for patients with therapy-related MDS, AML, acute lymphoblastic leukemia, or chronic myelomonocytic leukemia treated with allogeneic SCT.[120]
Sources: 111 · 112 · Level of evidence A1 · 120
Salvage autologous bone marrow or peripheral stem cell transplant after relapse from first transplant
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
After relapsing more than 24 months after autologous SCT, 174 patients received reinduction therapy and were then randomly assigned to receive either high-dose melphalan and salvage autologous SCT or oral weekly cyclophosphamide.[121] With a median follow-up of 52 months, the median OS was superior for salvage autologous SCT: 67 months (95% CI, 55–not estimable) versus 52 months (42–60) (HR, 0.56; 0.35–0.90; P = .017).[121,122][Level of evidence A1]
Sources: 121 · 121 · 122 · Level of evidence A1
In a retrospective review of 233 patients with refractory myeloma or relapsed and refractory myeloma who underwent a salvage autologous SCT, 81% of patients achieved a partial response (PR) or better.[123][Level of evidence C3]
Sources: 123 · Level of evidence C3
Maintenance Therapy
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Myeloma patients who respond to treatment show a progressive fall in the M protein until a plateau is reached; subsequent treatment with conventional doses does not result in any further improvement. This has led investigators to question how long treatment should be continued. No clinical trial has directly compared a consolidation approach with a maintenance approach to assess which is better in prolonging remission and, ultimately, survival.[124] Most clinical trials employ one or both.[125,126] Maintenance trials with glucocorticosteroids [127,128] and with interferon [129] showed very minor improvements in remission duration and survival but with toxicities that outweighed the benefits. The efficacy and tolerability of thalidomide, lenalidomide, bortezomib, and ixazomib in the induction and relapse settings has made these agents attractive options in maintenance trials.[124]
Maintenance therapy (lenalidomide, ixazomib, and daratumumab alone or in combination)
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Evidence (maintenance therapy [lenalidomide, ixazomib, and daratumumab alone or in combination]):
The prospective randomized AURIGA trial (NCT03901963) included 200 patients with newly diagnosed multiple myeloma who achieved a very good or better partial response, were MRD-positive on bone marrow (10-5), and who had not received daratumumab (or isatuximab) anti-CD38 therapy during induction therapy.[130] Patients were randomly assigned to receive either Dara-R or lenalidomide alone.
The prospective randomized AURIGA trial (NCT03901963) included 200 patients with newly diagnosed multiple myeloma who achieved a very good or better partial response, were MRD-positive on bone marrow (10-5), and who had not received daratumumab (or isatuximab) anti-CD38 therapy during induction therapy.[130] Patients were randomly assigned to receive either Dara-R or lenalidomide alone.
At a median follow-up of 32.3 months, the 30-month PFS rate was 82.7% for patients who received Dara-R and 66.4% for patients who received lenalidomide alone (HR, 0.53; 95% CI, 0.29–0.97; P = .036).[130][Level of evidence B1]
Sources: 130 · Level of evidence B1
The MRD-negative (10-6) conversion rate was 23.2% for patients who received Dara-R and 5.0% for patients who received lenalidomide alone (OR, 5.97; 95% CI, 2.15–16.58; P = .0002).
Grade 3 or 4 cytopenias occurred in 54.2% of patients who received Dara-R versus 46.9% of patients who received lenalidomide alone. Infections occurred in 18.8% of patients who received Dara-R versus 13.3% of patients who received lenalidomide alone.
A prospective randomized trial of 460 patients with newly diagnosed multiple myeloma who had completed induction therapy and autologous SCT compared lenalidomide maintenance with placebo.[131]
Sources: 131
A prospective randomized trial of 460 patients with newly diagnosed multiple myeloma who had completed induction therapy and autologous SCT compared lenalidomide maintenance with placebo.[131]
With a median follow-up of 91 months, the median OS for the lenalidomide maintenance group was 113.8 months (95% CI, 100.4−not reached) versus 84.1 months for the placebo group (range, 73.8−106.0 months; HR, 0.61; 95% CI, 0.46−0.80; P = .0004).[131][Level of evidence A1]
Sources: 131 · Level of evidence A1
This translated to a 5-year OS rate of 76% (95% CI, 70%−81%) for the lenalidomide group versus 64% (95% CI, 58%−70%) for the placebo group.
A prospective randomized trial evaluated lenalidomide maintenance in 1,917 patients newly diagnosed with or without transplant.[132]
Sources: 132
A prospective randomized trial evaluated lenalidomide maintenance in 1,917 patients newly diagnosed with or without transplant.[132]
With a median follow-up of 31 months, lenalidomide showed improved median PFS, 39 months (95% CI, 36−42) versus 20 months (range, 18−22) (HR, 0.46; 95% CI, 0.41−0.53; P < .0001), but lenalidomide failed to significantly improve the 3-year OS rate, 78.6% (95% CI, 75.6%−81.6%) versus 75.8% (72.4%−79.2%) (HR, 0.87; 95% CI, 0.73−1.05; P = .15).[132][Level of evidence B1]
Sources: 132 · Level of evidence B1
A meta-analysis included 1,208 patients with newly diagnosed disease who underwent an autologous SCT.[133]
Sources: 133
A meta-analysis included 1,208 patients with newly diagnosed disease who underwent an autologous SCT.[133]
With a median follow-up of 79.5 months, OS was not reached for the lenalidomide maintenance group versus 86 months for the placebo or observation group (HR, 0.75; 95% CI, 0.63‒0.90; P = .001).[133][Level of evidence A2]
Sources: 133 · Level of evidence A2
A meta-analysis of 7,730 patients in randomized clinical trials investigated lenalidomide or thalidomide maintenance in patients with newly diagnosed myeloma, with or without transplant.[134]
Sources: 134
A meta-analysis of 7,730 patients in randomized clinical trials investigated lenalidomide or thalidomide maintenance in patients with newly diagnosed myeloma, with or without transplant.[134]
The immunomodulatory maintenance therapy significantly improved PFS (HR, 0.62; 95% CI, 0.57−0.67; P < .001), but failed to significantly improve OS (HR, 0.93; 95% CI, 0.85−1.01; P = .082).[134][Level of evidence B1]
Sources: 134 · Level of evidence B1
A meta-analysis of 5,073 patients in randomized clinical trials investigated maintenance therapy in patients with newly diagnosed myeloma.[135]
Sources: 135
A meta-analysis of 5,073 patients in randomized clinical trials investigated maintenance therapy in patients with newly diagnosed myeloma.[135]
Lenalidomide (with or without prednisone) significantly improved PFS (HR, 0.47; 95% CI, 0.39−0.55), but also failed to significantly improve OS (HR, 0.76; 95% CI, 0.51−1.16).[135][Level of evidence B1]
Sources: 135 · Level of evidence B1
A prospective randomized trial of lenalidomide maintenance versus no maintenance after induction with melphalan and prednisone or melphalan, prednisone, and lenalidomide included patients aged 65 years and older who were not eligible for transplant.[27]
Sources: 27
A prospective randomized trial of lenalidomide maintenance versus no maintenance after induction with melphalan and prednisone or melphalan, prednisone, and lenalidomide included patients aged 65 years and older who were not eligible for transplant.[27]
The results showed a 66% reduction in the rate of progression (HR, 0.34; P < .001), which translated to an EFS of 31 months versus 14 months in favor of maintenance lenalidomide.[27][Level of evidence B1]
Sources: 27 · Level of evidence B1
A prospective randomized trial (CASSIOPEIA [NCT02541383]) evaluated daratumumab maintenance versus no maintenance for patients with newly diagnosed myeloma. Patients had already received bortezomib, thalidomide, and dexamethasone with or without daratumumab as induction before autologous SCT.[136]
Sources: CASSIOPEIA · 136
A prospective randomized trial (CASSIOPEIA [NCT02541383]) evaluated daratumumab maintenance versus no maintenance for patients with newly diagnosed myeloma. Patients had already received bortezomib, thalidomide, and dexamethasone with or without daratumumab as induction before autologous SCT.[136]
With a median follow-up of 35.4 months after maintenance randomization, the median PFS was not reached in the daratumumab arm and was 46.7 months (40.0–not evaluable) with observation only (HR, 0.53; 95% CI, 0.42–0.68; P < .0001).[136][Level of evidence B1]
Sources: 136 · Level of evidence B1
A prospective randomized trial evaluated ixazomib maintenance versus no maintenance for patients with newly diagnosed myeloma who were not undergoing autologous SCT after induction therapy.[137]
Sources: 137
A prospective randomized trial evaluated ixazomib maintenance versus no maintenance for patients with newly diagnosed myeloma who were not undergoing autologous SCT after induction therapy.[137]
With a median follow-up of 41 months, the median PFS favored ixazomib maintenance at 17.4 months versus 9.4 months (HR, 0.66; 95% CI, 0.54–0.80; P < .001).[137][Level of evidence B1]
Sources: 137 · Level of evidence B1
A prospective trial (NCT02659293) evaluated maintenance therapy in patients with newly diagnosed melanoma who had received induction therapy and autologous SCT. Patients were randomly assigned to receive maintenance therapy with either 3 years of carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone.[138]
Sources: NCT02659293 · 138
A prospective trial (NCT02659293) evaluated maintenance therapy in patients with newly diagnosed melanoma who had received induction therapy and autologous SCT. Patients were randomly assigned to receive maintenance therapy with either 3 years of carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone.[138]
With a median follow-up of 33.8 months, the median PFS was 59.1 months for patients who received the triplet maintenance therapy and 41.4 months for patients who received lenalidomide alone (HR, 0.51; 95% CI, 0.31–0.86; P = .012).[138][Level of evidence B1]
Sources: 138 · Level of evidence B1
Toxicity and efficacy data are not mature.[138]
Sources: 138
All the trials and meta-analyses of lenalidomide maintenance showed a significant improvement in PFS, while OS was improved in one trial and one meta-analysis, both after autologous SCT. All of these trials showed an increase in myelodysplasia or acute leukemia from 3% to 7% for lenalidomide, consistent with other studies of lenalidomide. This increased risk is mostly seen in patients with previous exposure to alkylating agents. Doses of 5 mg to 15 mg a day have been used either continuously or with 1 week off every month.
One prospective trial found improved benefit in PFS for Dara-R compared with lenalidomide alone in a population that had undergone transplant and was naïve to anti-CD38 therapy.[130] One trial establishing the D-VRd regimen for newly diagnosed patients included Dara-R maintenance (for 2 to 3 years or longer) in the D-VRd induction arm.[57] The incremental impact of Dara-R maintenance therapy in patients who received daratumumab induction therapy has not been established. It is also unclear if patients with MRD-negative (10-5) disease after induction therapy and transplant would benefit similarly since they were also not studied.[139]
Among 556 patients in the Myeloma XI trial (NCT01554852), those with del(1p), del(17p), and t(4;14) had a median PFS of 57.3 months with lenalidomide maintenance and 10.9 months with observation.[140] For patients unable to receive lenalidomide maintenance, ixazomib is a reasonable alternative. Although maintenance therapy with carfilzomib, lenalidomide, and dexamethasone resulted in improved PFS when compared with lenalidomide alone, the preliminary toxicity and efficacy results must mature before implementing this regimen.[138]
Sources: Myeloma XI · 140 · 138
Proteasome inhibitor maintenance therapy
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Evidence (proteasome inhibitor maintenance therapy):
In a prospective randomized trial of 656 newly diagnosed patients with at least a PR after standard induction therapy followed by autologous SCT, ixazomib (the oral proteasome inhibitor) was compared with placebo.[141]
Sources: 141
In a prospective randomized trial of 656 newly diagnosed patients with at least a PR after standard induction therapy followed by autologous SCT, ixazomib (the oral proteasome inhibitor) was compared with placebo.[141]
With a median follow-up of 31 months, the ixazomib maintenance improved medial PFS, 26.5 months (95% CI, 23.7−33.8) versus 21.3 months (95% CI, 18.0−24.7) (HR, 0.72; 95% CI, 0.58−0.89; P = .0023).[141][Level of evidence B1] There was no increase in second malignancies with the proteasome inhibitor (3% for both groups).
Sources: 141 · Level of evidence B1
In 511 previously untreated patients not eligible for transplant and aged 65 years or older, a randomized comparison of bortezomib, melphalan, prednisone, thalidomide and subsequent maintenance using bortezomib plus thalidomide versus VMP (with no maintenance) showed superiority of the arm with thalidomide and bortezomib during induction and maintenance.
In 511 previously untreated patients not eligible for transplant and aged 65 years or older, a randomized comparison of bortezomib, melphalan, prednisone, thalidomide and subsequent maintenance using bortezomib plus thalidomide versus VMP (with no maintenance) showed superiority of the arm with thalidomide and bortezomib during induction and maintenance.
With a median follow-up of 47 months, the 3-year PFS rate was 55% versus 33% (P < .01), and the 5-year OS rate was 59% versus 46% (P = .04).[142][Level of evidence A1]
Sources: 142 · Level of evidence A1
Because of trial design, it is unclear whether the improved results were caused by the addition of thalidomide during the induction or by the use of maintenance therapy with bortezomib and thalidomide.
Summary: After autologous SCT, patients are offered lenalidomide maintenance therapy based on the consistent PFS and occasional OS benefits previously described. But short-term and long-term toxicities, and financial toxicities, may prevent implementation.[143,144] High-risk patients, especially those with del(17p) or t(14;16), may require bortezomib maintenance (with or without lenalidomide), but this approach is not evidence-based and confirmatory clinical trials are required.[145,146]
Management and Prevention of Myeloma Bone Disease
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Myeloma bone disease is a consequence of increased osteoclastic activity, and agents that inhibit osteoclasts are an important component of myeloma therapy.[9] The bisphosphonates pamidronate and zoledronate are used most often, via IV infusion, but the RANKL monoclonal antibody inhibitor denosumab, given subcutaneously, is also effective, especially when renal dysfunction precludes the use of bisphosphonates.[8,9]
Zoledronate (bisphosphonate)
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Evidence (zoledronate):
A prospective randomized trial of 1,970 patients compared IV zoledronate with oral clodronate in newly diagnosed patients receiving induction chemotherapy with or without consolidation.[147]
Sources: 147
A prospective randomized trial of 1,970 patients compared IV zoledronate with oral clodronate in newly diagnosed patients receiving induction chemotherapy with or without consolidation.[147]
With a median follow-up of 3.7 years, zoledronate improved median OS from 44.5 months to 50.0 months (HR, 0.84; 95% CI, 0.74–0.96; P = .0118).[147][Level of evidence A1]
Sources: 147 · Level of evidence A1
In this trial, both bisphosphonates were continued until time of relapse. As expected, skeletal-related events were also reduced in the zoledronate group (27% vs. 35%; P = .004).[148,149]
The improvement of median OS with zoledronate was confirmed in a Cochrane network meta-analysis.[150][Level of evidence A2] This meta-analysis also showed that 6 to 15 patients need treatment with bisphosphonates to prevent one skeletal-related event.
Sources: 150 · Level of evidence A2
A clinical trial of zoledronate given once a month compared with zoledronate given every 12 weeks showed noninferiority for the 12-week regimen in 1,822 patients with bone metastases from breast cancer, prostate cancer, or multiple myeloma.[151] However, this study included only 278 patients with myeloma, and evaluation of this subgroup was insufficiently powered to establish noninferiority for the 12-week regimen. Nonetheless, this trial is used as justification for implementing a 12-week schedule at the start of therapy or as soon as maximal response has been reached.
Sources: 151
Bisphosphonates are associated with infrequent long-term complications (in 3%–5% of patients), including osteonecrosis of the jaw and avascular necrosis of the hip.[152,153] For more information about osteonecrosis of the jaw, see Oral Complications of Cancer Therapies. These side effects must be balanced against the potential benefits of bisphosphonates when bone metastases are evident.[154] Bisphosphonates are usually given IV on a monthly basis for 2 years and then extended at the same schedule or at a reduced schedule (i.e., once every 3–4 months), if there is evidence of active myeloma bone disease.[155,156] On the aforementioned randomized trial,[148] which showed OS advantage, patients received bisphosphonates monthly until time of relapse.
Sources: 152 · 153 · Oral Complications of Cancer Therapies · 154 · 155 · 156 · 148
Pamidronate (bisphosphonate)
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Evidence (pamidronate):
A randomized, double-blind study of patients with stage III myeloma showed that monthly IV pamidronate significantly reduced pathological fractures, bone pain, spinal cord compression, and the need for bone radiation therapy (38% skeletal-related events were reported in the treatment group vs. 51% in the placebo group after 21 months of therapy; P = .015).[157][Level of evidence B1] For more information about bisphosphonate therapy, see the Pharmacological Therapies for Pain Control section in Cancer Pain.
Sources: 157 · Level of evidence B1 · Pharmacological Therapies for Pain Control
A double-blind, randomized, controlled trial of 504 patients with newly diagnosed multiple myeloma compared 30 mg of pamidronate to 90 mg of pamidronate. The study found that there was no difference in skeletal-related events, but there was less osteonecrosis (2 events vs. 8 events) seen in the low-dose group.[158][Level of evidence B3]
Sources: 158 · Level of evidence B3
A randomized comparison of pamidronate versus zoledronic acid in 518 patients with multiple myeloma showed equivalent efficacy in regard to skeletal-related complications (both were given for 2 years).[159][Level of evidence B1]
Sources: 159 · Level of evidence B1
Denosumab (RANKL inhibitor)
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Evidence (denosumab):
In a prospective randomized double-blind trial, 1,718 patients with newly diagnosed myeloma and at least one documented lytic bone lesion received either zoledronate or denosumab.[8]
Sources: 8
In a prospective randomized double-blind trial, 1,718 patients with newly diagnosed myeloma and at least one documented lytic bone lesion received either zoledronate or denosumab.[8]
The study met its primary end point of noninferiority for denosumab compared with zoledronate (HR, 0.98; 95% CI, 0.85‒1.14; P = .01 for noninferiority).[8]
Sources: 8
Denosumab is significantly more expensive than the bisphosphonates, which are available in generic form.
Unlike bisphosphonates, the reversible mechanism of action for denosumab may result in rebound fractures if it is discontinued, although this theoretical concern for patients with myeloma may be mitigated by continuous maintenance therapy.[160]
Sources: 160
Radiation therapy for bone lesions
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Lytic lesions of the spine generally require radiation if any of the following are true:
They are associated with an extramedullary (paraspinal) plasmacytoma.
A painful destruction of a vertebral body occurred.
CT or MRI scans present evidence of spinal cord compression.[161]
Sources: 161
Back pain caused by osteoporosis and small compression fractures of the vertebrae responds best to chemotherapy.
Extensive radiation of the spine or long bones for diffuse osteoporosis may lead to prolonged suppression of hemopoiesis and is rarely indicated.[162]
Sources: 162
Bisphosphonates are useful for slowing or reversing the osteopenia that is common in patients with myeloma.[157]
Sources: 157
Treatment of Relapsed or Refractory Multiple Myeloma
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Treatment Options for Relapsed or Refractory Multiple Myeloma
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Relapses occur for almost all patients after induction therapy, consolidation with autologous stem cell transplant (SCT), and maintenance therapy. During initial therapy, some patients have poor disease response, or their disease progresses. The general strategy is to give new therapies sequentially as required. In fit patients, reinduction therapy with response may be consolidated with an autologous SCT or allogeneic SCT in some cases. Sometimes, when relapse occurs 1 year or more after initial therapy, the same drugs can be administered a second time.
A subgroup of patients who do not achieve a response to induction chemotherapy have stable disease and a survival prognosis that is as good as that for responding patients.[1,2] When the stable nature of the disease becomes established, these patients can discontinue therapy until the myeloma begins to progress again. Other patients with primary refractory myeloma and progressive disease require a change in therapy. For more information, see the Treatment of Multiple Myeloma section.
Sources: 1 · 2 · Treatment of Multiple Myeloma
For patients with disease response to initial therapy, the myeloma growth rate, as measured by the monoclonal (or myeloma) protein-doubling time, increases progressively with each subsequent relapse, and remission durations become shorter and shorter. Marrow function becomes increasingly compromised as patients develop pancytopenia and enter a refractory phase; occasionally, the myeloma cells dedifferentiate and extramedullary plasmacytomas develop. The myeloma cells may still be sensitive to chemotherapy, but the regrowth rate during relapse is so rapid that progressive improvement is not observed.
Combinations of drugs or single agents may be given sequentially as required. The goal is to avoid symptoms and adverse consequences of relapsing disease. However, the onset of therapy may be delayed because of slow disease progression and good performance status.
Treatment options for relapsed or refractory multiple myeloma include:
Monoclonal antibodies.
Sources: Monoclonal antibodies
Elotuzumab.
Sources: Elotuzumab
Isatuximab.
Sources: Isatuximab
Proteasome inhibitors.
Sources: Proteasome inhibitors
Carfilzomib.
Sources: Carfilzomib
Ixazomib.
Sources: Ixazomib
Chimeric antigen receptor (CAR) T-cell therapy.
Chimeric antigen receptor (CAR) T-cell therapy.
Ciltacabtagene autoleucel (cilta-cel).
Idecabtagene vicleucel (ide-cel).
Sources: Idecabtagene vicleucel (ide-cel)
Bispecific antibody therapy.
Sources: Bispecific antibody therapy
Talquetamab.
Sources: Talquetamab
Elranatamab.
Sources: Elranatamab
Immunomodulatory agents.
Sources: Immunomodulatory agents
Lenalidomide.
Sources: Lenalidomide
Thalidomide.
Sources: Thalidomide
B-cell maturation antigen (BCMA)-targeting antibody-drug conjugates.
Sources: B-cell maturation antigen (BCMA)-targeting antibody-drug conjugates
B-cell maturation antigen (BCMA)-targeting antibody-drug conjugates.
Belantamab mafodotin.
Sources: Belantamab mafodotin
Chemotherapy (cytotoxic agents).
Sources: Chemotherapy (cytotoxic agents)
Selinexor.
Sources: Selinexor
Venetoclax.
Sources: Venetoclax
BRAF/MEK inhibitors.
Sources: BRAF/MEK inhibitors
Corticosteroids.
Sources: Corticosteroids
Monoclonal antibodies
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Daratumumab
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Daratumumab is a monoclonal antibody targeting CD38 that can be given on its own but is usually given in combination with other drugs. Although it is given as an infusion, the subcutaneous formulation has equivalent efficacy and fewer adverse events.[3]
Sources: 3
Evidence (daratumumab):
In the prospective CASTOR trial (NCT02136134), 498 previously treated patients were randomly assigned to receive either daratumumab, bortezomib, and dexamethasone (DVd) or bortezomib and dexamethasone (Vd).[4]
In the prospective CASTOR trial (NCT02136134), 498 previously treated patients were randomly assigned to receive either daratumumab, bortezomib, and dexamethasone (DVd) or bortezomib and dexamethasone (Vd).[4]
With a median follow-up of 72.6 months, the median overall survival (OS) was 49.6 months for patients in the DVd group and 38.5 months for patients in the Vd group (hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.59–0.92; P = .0075).[4][Level of evidence A1]
Sources: 4 · Level of evidence A1
In the prospective POLLUX trial (NCT02076009), 569 previously treated patients were randomly assigned to receive either daratumumab, lenalidomide, and dexamethasone (DRd) or lenalidomide and dexamethasone (Rd).[5,6]
In the prospective POLLUX trial (NCT02076009), 569 previously treated patients were randomly assigned to receive either daratumumab, lenalidomide, and dexamethasone (DRd) or lenalidomide and dexamethasone (Rd).[5,6]
With a median follow-up of 79.7 months, the median OS was 67.6 months for patients in the DRd group and 51.8 months for patients in the Rd group (HR, 0.73; 95% CI, 0.58–0.91; P = .0044).[6][Level of evidence A1]
Sources: 6 · Level of evidence A1
In a prospective trial (NCT03158688), 466 previously treated patients were randomly assigned in a 2:1 ratio to receive either daratumumab, carfilzomib, and dexamethasone or carfilzomib and dexamethasone.[7]
Sources: NCT03158688 · 7
In a prospective trial (NCT03158688), 466 previously treated patients were randomly assigned in a 2:1 ratio to receive either daratumumab, carfilzomib, and dexamethasone or carfilzomib and dexamethasone.[7]
With a median follow-up of 27.8 months, the median progression-free survival (PFS) was 28.6 months (95% CI, 25.6–29.5) in the daratumumab group and 15.2 months (11.1–19.9) in the control arm (log-rank P < .0001).[8][Level of evidence B1]
Sources: 8 · Level of evidence B1
In a prospective randomized trial, 1,304 previously treated patients received either daratumumab plus pomalidomide and dexamethasone (DPd) or pomalidomide and dexamethasone (Pd) alone.[9]
Sources: 9
In a prospective randomized trial, 1,304 previously treated patients received either daratumumab plus pomalidomide and dexamethasone (DPd) or pomalidomide and dexamethasone (Pd) alone.[9]
With a median follow-up of 16.9 months, the median PFS was 12.4 months (95% CI, 8.3–19.3) for patients who received DPd and 6.9 months (95% CI, 5.5–9.3) for patients who received Pd (HR, 0.63; 95% CI, 0.47–0.85; P = .0018).[9][Level of evidence B1]
Sources: 9 · Level of evidence B1
Several phase I and phase II trials evaluated daratumumab as a single agent for relapsed or refractory multiple myeloma.[10-12]
Several phase I and phase II trials evaluated daratumumab as a single agent for relapsed or refractory multiple myeloma.[10-12]
With a median follow-up of 12 to 17 months, the overall response rate was 31% and 36%, with minimal response or stable disease in about 40% of patients.[10-12][Level of evidence C3]
Sources: 10 · 12 · Level of evidence C3
In every prospective randomized trial to date, adding daratumumab to other active myeloma combination therapies improved responses and PFS when compared with the combination therapies alone.
Elotuzumab
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Elotuzumab is a monoclonal antibody directed at SLAMF7 (signaling lymphocytic activation molecule F7).
Evidence (elotuzumab):
A prospective trial (ELOQUENT-3 [NCT02654132]) included 117 patients with relapsed or refractory disease after both lenalidomide and a proteasome inhibitor. Patients were randomly assigned to receive either elotuzumab, pomalidomide, and dexamethasone (EPd) or Pd.[13]
Sources: ELOQUENT-3 · 13
A prospective trial (ELOQUENT-3 [NCT02654132]) included 117 patients with relapsed or refractory disease after both lenalidomide and a proteasome inhibitor. Patients were randomly assigned to receive either elotuzumab, pomalidomide, and dexamethasone (EPd) or Pd.[13]
With a median follow-up of 45 months, the median OS was 29.8 months (22.9–45.7) for patients who received EPd compared with 17.4 months (13.8–27.7) for patients who received Pd (HR, 0.59; 95% CI, 0.37–0.93; P = .0217).[13][Level of evidence A1]
Sources: 13 · Level of evidence A1
In a prospective randomized trial (ELOQUENT-2 [NCT01239797]) of 646 patients with relapsed or refractory myeloma, elotuzumab was combined with lenalidomide and dexamethasone and compared with Rd alone.[14][Level of evidence A1]
Sources: ELOQUENT-2 · 14 · Level of evidence A1
In a prospective randomized trial (ELOQUENT-2 [NCT01239797]) of 646 patients with relapsed or refractory myeloma, elotuzumab was combined with lenalidomide and dexamethasone and compared with Rd alone.[14][Level of evidence A1]
With a median follow-up of 70.6 months, the 5-year PFS rate was 17% in the elotuzumab group and 11% in the Rd group (HR, 0.73; 95% CI, 0.60–0.89; P = .0014). The 5-year OS rate was 40% in the elotuzumab group and 33% in the Rd group (HR, 0.82; 95.4% CI, 0.68–1.00; P = .0408).[14]
Sources: 14
Isatuximab
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Isatuximab is a monoclonal antibody directed against CD38.
Evidence (isatuximab):
In a prospective randomized trial of 387 patients with relapsed or refractory disease, Pd was given with or without isatuximab.[15]
Sources: 15
In a prospective randomized trial of 387 patients with relapsed or refractory disease, Pd was given with or without isatuximab.[15]
With a median follow-up of 35.3 months, the median OS was 24.6 months (95% CI, 20.3–31.3) for patients who received isatuximab plus PD and 17.7 months (95% CI, 14.4–26.2) for patients who received Pd alone (HR, 0.76; 95% CI, 0.57–1.01; 2-sided P = .056).
Similarly, the median PFS was 17.5 months (95% CI, 14.9–19.2) for the isatuximab group and 12.9 months (95% CI, 10.1–16.6) for the Pd group (HR, 0.76; 95% CI, 0.58–0.99; P = .020).[15][Level of evidence B1]
Sources: 15 · Level of evidence B1
In a prospective randomized trial of 302 patients with relapsed or refractory disease, the combination of carfilzomib and dexamethasone was given with or without isatuximab.
In a prospective randomized trial of 302 patients with relapsed or refractory disease, the combination of carfilzomib and dexamethasone was given with or without isatuximab.
With a median follow-up of 20.7 months, the 2-year PFS rate was 68.9% (95% CI, 60.7%–75.8%) for patients who received isatuximab group and 45.7% (95% CI, 35.2%–55.6%) for patients who received carfilzomib and dexamethasone alone (HR, 0.53; 99% CI, 0.32–0.89; 2-sided P = .0014).[16][Level of evidence B1]
Sources: 16 · Level of evidence B1
There are no data comparing isatuximab with daratumumab, both of which target CD38. There are no data proving that isatuximab has efficacy in patients with disease that is resistant to daratumumab.
Proteasome inhibitors
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Bortezomib
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Bortezomib is the first-in-class proteasome inhibitor that is given subcutaneously on a weekly basis for 3 of every 4 weeks; the subcutaneous route is preferred to the intravenous (IV) route because it causes significantly less neuropathy and no loss of responsiveness.[17-19] Bortezomib is metabolized and cleared by the liver, and it appears to be active and well tolerated in patients with renal impairment.[20,21] More than 6 months after completion of bortezomib induction therapy, bortezomib can be given again with a 40% overall response rate, according to a meta-analysis of 23 phase II studies.[22][Level of evidence C3]
Evidence (bortezomib):
A prospective randomized study of 669 patients with relapsed myeloma compared bortezomib given by IV with high-dose oral dexamethasone.[23]
Sources: 23
A prospective randomized study of 669 patients with relapsed myeloma compared bortezomib given by IV with high-dose oral dexamethasone.[23]
With a median follow-up of 22 months, the median OS was 29.8 months for bortezomib versus 23.7 months for dexamethasone (HR, 0.77; P = .027) even though the trial allowed crossover after relapse.[23][Level of evidence A1]
Sources: 23 · Level of evidence A1
A prospective randomized trial (NCT00103506) of 646 previously treated patients compared bortezomib plus pegylated liposomal doxorubicin with bortezomib alone.[24]
Sources: NCT00103506 · 24
A prospective randomized trial (NCT00103506) of 646 previously treated patients compared bortezomib plus pegylated liposomal doxorubicin with bortezomib alone.[24]
With a median follow-up of 7.0 months, 1-year OS rates were better in patients who received the combination (82% vs. 75%; P = .05).[24][Level of evidence A1]
Sources: 24 · Level of evidence A1
A prospective randomized trial of 260 newly diagnosed patients aged 65 years and older compared bortezomib, melphalan, and prednisone (VMP) with bortezomib, thalidomide, and prednisone (VTP).[25]
Sources: 25
A prospective randomized trial of 260 newly diagnosed patients aged 65 years and older compared bortezomib, melphalan, and prednisone (VMP) with bortezomib, thalidomide, and prednisone (VTP).[25]
With a median follow-up of 72 months, the median OS favored the VMP arm, 63 months versus 43 months for the VTP group (HR, 0.67; 95% CI, 0.49–0.91; P = .01).[25][Level of evidence A1]
Sources: 25 · Level of evidence A1
Carfilzomib
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Carfilzomib is a second-generation proteasome inhibitor that is given by IV (unlike the subcutaneous route for bortezomib). Most studies have used twice-weekly administration, but once-weekly administration appears at least equally efficacious and safe.[26]
Sources: 26
Evidence (carfilzomib):
A prospective randomized trial included 578 patients with relapsed or refractory myeloma.[26]
Sources: 26
A prospective randomized trial included 578 patients with relapsed or refractory myeloma.[26]
The median PFS of patients who received carfilzomib once a week was significantly better (11.2 months; 95% CI, 8.6‒13.0) than twice a week (7.6 months; 95% CI, 5.8‒9.2) (HR, 0.69; 95% CI, 0.54‒0.83; P = .0029).[26][Level of evidence B1]
Sources: 26 · Level of evidence B1
In a prospective randomized trial of 792 patients with relapsed or refractory myeloma, the combination of carfilzomib, lenalidomide, and dexamethasone was compared with Rd.[27]
Sources: 27
In a prospective randomized trial of 792 patients with relapsed or refractory myeloma, the combination of carfilzomib, lenalidomide, and dexamethasone was compared with Rd.[27]
With a median follow-up of 67.1 months, median OS in the carfilzomib arm was 48.3 months (95% CI, 42.4‒52.8) versus 40.4 months (95% CI, 33.6‒44.4) (HR, 0.79; 95% CI, 0.67‒0.95; one-sided P = .009).[27][Level of evidence A1]
Sources: 27 · Level of evidence A1
In a preplanned subgroup analysis, patients with high-risk cytogenetics (i.e., t(4;14), t(14;16), del(17p)) also had improved PFS with the triplet regimen (23 months vs. 14 months; HR, 0.70; 95% CI, 0.43−1.16; one-sided P = .083). Response rates were also improved, but the carfilzomib combination did not abrogate the worse prognosis.[28][Level of evidence B3]
Sources: 28 · Level of evidence B3
A prospective randomized study (NCT01568866) of 929 patients compared carfilzomib and dexamethasone with bortezomib and dexamethasone.[29]
Sources: NCT01568866 · 29
A prospective randomized study (NCT01568866) of 929 patients compared carfilzomib and dexamethasone with bortezomib and dexamethasone.[29]
With a median follow-up of 37 months, the median OS was 47.6 months (95% CI, 42.5–not evaluable) for the carfilzomib combination compared with 40.0 months (95% CI, 32.6–42.3) for the bortezomib combination (HR, 0.79; 95% CI, 0.65–0.96; P = .020).[29][Level of evidence A1]
Sources: 29 · Level of evidence A1
Cardiovascular adverse events such as heart failure, chest pain, and acute coronary syndrome (grade 3 or higher) occurred in 25% of patients, especially in the first 3 months of therapy.[30,31]
A systematic review and meta-analysis demonstrated that renal adverse events occurred in 21% of patients of patients who received carfilzomib, and 8.3% had grade 3 to 5 toxicities. Acute kidney injury was the most common renal toxicity.[32]
Sources: 32
Ixazomib
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Ixazomib is a second-generation proteasome inhibitor that is given orally on a weekly basis for 3 of every 4 weeks.
Evidence (ixazomib):
In a prospective randomized trial involving 722 patients with relapsed or refractory myeloma, ixazomib combined with lenalidomide and dexamethasone was compared with a placebo combined with lenalidomide and dexamethasone.[33,34]
In a prospective randomized trial involving 722 patients with relapsed or refractory myeloma, ixazomib combined with lenalidomide and dexamethasone was compared with a placebo combined with lenalidomide and dexamethasone.[33,34]
With a median follow-up of 2 years, the median PFS was 20.6 months in the ixazomib group versus 14.7 months for the placebo group (HR, 0.66; 95% CI, 0.47–0.93; P = .016).[33][Level of evidence B1]
Sources: 33 · Level of evidence B1
Improved PFS was also seen for high-risk patients (defined by fluorescence in situ hybridization and cytogenetics).[34][Level of evidence B1]
Sources: 34 · Level of evidence B1
No grade 3 or 4 neuropathy was seen in any patient treated with ixazomib.
With a median follow-up of 85 months, there was little difference in the median OS at 53.6 months for the ixazomib group and 51.6 months for the placebo group (HR, 0.939; P = .49).[35][Level of evidence B1 based on PFS, as noted above]
Sources: 35 · Level of evidence B1
A prospective randomized trial (NCT01850524) included 705 patients with newly diagnosed, transplant-eligible multiple myeloma. The study compared ixazomib combined with lenalidomide and dexamethasone with a placebo combined with lenalidomide and dexamethasone.[36]
Sources: NCT01850524 · 36
A prospective randomized trial (NCT01850524) included 705 patients with newly diagnosed, transplant-eligible multiple myeloma. The study compared ixazomib combined with lenalidomide and dexamethasone with a placebo combined with lenalidomide and dexamethasone.[36]
With a median follow-up of 53.3 to 55.8 months for each arm, the median PFS was 35.3 months in the ixazomib group versus 21.8 months in the placebo group (HR, 0.830; 95% CI, 0.676–1.018; P = .073).[36][Level of evidence B1] This difference did not meet statistical significance for PFS.
Sources: 36 · Level of evidence B1
A prospective randomized trial of patients with relapsed myeloma undergoing a second autologous SCT compared consolidation and maintenance therapy with ixazomib versus observation alone.[37]
Sources: 37
A prospective randomized trial of patients with relapsed myeloma undergoing a second autologous SCT compared consolidation and maintenance therapy with ixazomib versus observation alone.[37]
With a median follow-up of 27 months, the median PFS was 20 months in the consolidation and maintenance therapy group and 13 months in the observation group (HR, 0.55; 95% CI, 0.39–0.78; P = .0006).[37][Level of evidence B1]
Sources: 37 · Level of evidence B1
CAR T-cell therapy
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
CAR T-cell therapy is a cellular therapy for refractory and/or multiply relapsed myeloma. This therapy consists of autologous anti-BCMA transduced T cells. This therapy has shown a 50% to 65% complete remission rate and a median PFS of 18 to 20 months in patients from highly selected nonrandomized series.[38-40][Level of evidence C3] Based on the durable responses in these nonrandomized series, the U.S. Food and Drug Administration (FDA) approved the BCMA-directed CAR T-cell products idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) for patients with relapsed or refractory disease. A review of the management of moderate-to-severe immune-related adverse events suggests immediate use of corticosteroids and supportive hospital care.[41] Other molecular targets and expanded clinical approaches are being investigated.[42][Level of evidence C3]
Sources: 38 · 40 · Level of evidence C3 · 41 · 42 · Level of evidence C3
Ciltacabtagene autoleucel
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Evidence (cilta-cel):
A prospective randomized trial (NCT04181827) included 419 patients with relapsed myeloma after one to three prior lines of treatment who also had lenalidomide-refractory disease. Patients received either CAR T-cell therapy with cilta-cel or the standard of care at the discretion of physicians.[43]Based on this trial, the FDA approved cilta-cel for patients with (1) relapsed or refractory myeloma after at least one line of therapy including a proteosome inhibitor (such as bortezomib) and an immunomodulatory agent (such as lenalidomide) AND (2) lenalidomide-refractory disease.
Sources: NCT04181827 · 43
A prospective randomized trial (NCT04181827) included 419 patients with relapsed myeloma after one to three prior lines of treatment who also had lenalidomide-refractory disease. Patients received either CAR T-cell therapy with cilta-cel or the standard of care at the discretion of physicians.[43]Based on this trial, the FDA approved cilta-cel for patients with (1) relapsed or refractory myeloma after at least one line of therapy including a proteosome inhibitor (such as bortezomib) and an immunomodulatory agent (such as lenalidomide) AND (2) lenalidomide-refractory disease.
With a median follow-up of 15.9 months, the 12-month PFS rate was 75.9% (95% CI, 69.4%–81.1%) in the cilta-cel group and 48.6% (95% CI, 41.5%–55.3%) in the standard-of-care group (HR, 0.26; 95% CI, 0.18–0.38; P < .001).[43][Level of evidence B1]
Sources: 43 · Level of evidence B1
No difference in OS was reported. Grade 3 or higher cytokine-release syndrome occurred in 1.1% of patients in the CAR T-cell therapy group, and no patients had grade 3 or higher neurotoxicity.
Two patients developed a T-cell lymphoma on the skin at 5 and 16 months after cilta-cell infusion, and the T cells had detectable CAR transgenic expression and integration.[44] Both patients attained a complete response with lymphoma-directed therapy.
Sources: 44
A quality-of-life evaluation showed significant improvement in global health status and visual analogue scale responses for patients who received cilta-cel.[45][Level of evidence A3]
Sources: 45 · Level of evidence A3
Idecabtagene vicleucel (ide-cel)
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Evidence (ide-cel):
A prospective randomized trial (NCT03651128) included 386 patients with relapsed or refractory myeloma after two to four prior lines of treatment who also had lenalidomide-refractory disease. Patients received either CAR T-cell therapy with ide-cel or one of five standard alternative regimens.[46,47]Based on this trial, the FDA approved ide-cel for patients with (1) relapsed or refractory myeloma after at least two lines of therapy AND (2) lenalidomide-refractory disease.
Sources: NCT03651128 · 46 · 47
A prospective randomized trial (NCT03651128) included 386 patients with relapsed or refractory myeloma after two to four prior lines of treatment who also had lenalidomide-refractory disease. Patients received either CAR T-cell therapy with ide-cel or one of five standard alternative regimens.[46,47]Based on this trial, the FDA approved ide-cel for patients with (1) relapsed or refractory myeloma after at least two lines of therapy AND (2) lenalidomide-refractory disease.
With a median follow-up of 30.9 months, the median PFS was 13.8 months in the ide-cel group versus 4.4 months in the standard-regimen group (HR, 0.49; 95% CI, 0.38–0.63; P < .0001).[47][Level of evidence B1]
Sources: 47 · Level of evidence B1
The overall and complete response rates were higher in patients who received ide-cel (71% and 39%, respectively) than in patients who received the standard regimens (42% and 5%, respectively).
Grade 3 or 4 adverse events occurred in 93% of patients who received ide-cel and 75% who received a standard regimen. Ide-cel was associated with cytokine-release syndrome in 88% of patients (grade 3 or higher in 5% of patients) and with neurological symptoms in 15% of patients (grade 3 or higher in 3% of patients).
Bispecific antibody therapy
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Teclistamab
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Teclistamab is a T-cell-redirecting bispecific antibody.
Evidence (teclistamab):
In a phase I/II study (NCT03145181 and NCT04557098), teclistamab was given to 165 patients with relapsed or refractory myeloma who received at last four prior systemic treatments.[50]
Sources: NCT03145181 · NCT04557098 · 50
In a phase I/II study (NCT03145181 and NCT04557098), teclistamab was given to 165 patients with relapsed or refractory myeloma who received at last four prior systemic treatments.[50]
With a median follow-up of 14.1 months, the overall response rate was 63.0%, with a complete response rate of 39.4%. The median PFS was 11.3 months (95% CI, 8.8–17.1).[50][Level of evidence C3]
Sources: 50 · Level of evidence C3
Side effects included cytokine release syndrome in 72% of patients (grade 3 or 4 in only one patient) and hematologic toxicity (grade 3 or 4) in 61% of patients, including febrile neutropenia (44.8%).
Of the 165 patients, 40 patients who had received prior anti-BCMA therapy (an antibody-drug conjugate or CAR T-cell therapy) were assessed at a median follow-up of 28.0 months.[51] The overall response rate was 52.5%. A total of 47.5% of patients had a very good partial response or better, and 30.0% of patients had a complete response or better. The median duration of response was 14.8 months.[51][Level of evidence C3]
Sources: 51 · 51 · Level of evidence C3
Patients receiving teclistamab can be given replacement immunoglobulin G IV or subcutaneously every 2 to 4 weeks to reduce the risk of infection.[52] Replacement of immunoglobulin G may be applicable for patients receiving other bispecific antibodies.
Sources: 52
Talquetamab
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Talquetamab is a T-cell-redirecting bispecific antibody that targets GPRC5D, a receptor highly expressed on plasma cells, along with CD3.
Evidence (talquetamab):
In a phase II study, talquetamab was given to 232 patients with relapsed or refractory myeloma who had received at least four prior systemic treatments.[53]
Sources: 53
In a phase II study, talquetamab was given to 232 patients with relapsed or refractory myeloma who had received at least four prior systemic treatments.[53]
At a median follow-up of 11.7 months, the overall response rate was 73.6% (95% CI, 63%–82.4%). Approximately 85% of responders were still in remission by 9 months.[53,54][Level of evidence C3]
Sources: 53 · 54 · Level of evidence C3
Cytokine release syndrome occurred in up to 89% patients and was grade 1 or 2 in all but one case. Skin-related events and dysgeusia occurred in 60% to 70% of patients.
Elranatamab
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Elranatamab is a T-cell directing bispecific antibody targeting BCMA and CD3.
Evidence (elranatamab):
Elranatamab was given to 187 patients with relapsed or refractory myeloma who received at least four prior lines of therapy.[55]
Sources: 55
Elranatamab was given to 187 patients with relapsed or refractory myeloma who received at least four prior lines of therapy.[55]
With a median follow-up of 14.7 months, the objective response rate was 61% (95% CI, 51.8%–69.6%), and 35% of patients achieved a complete response. The 15-month PFS rate was 50.9% (95% CI, 40.9%–60.0%).[55][Level of evidence C3]
Sources: 55 · Level of evidence C3
Summary: Patients with myeloma who have received one to four prior lines of therapy, are refractory to proteosome inhibitors and immunomodulatory agents, and are also experiencing a slow relapse are often referred for CAR T-cell therapy. This is because delays in production of the CAR T-cell agent are less problematic, and because time receiving therapy is fixed and short-term, allowing a long duration therapy-free time after a response.[49] Patients who experience a quick relapse may benefit from an "off-the-shelf" bispecific antibody that results in similar response rates and durability of response, but this approach comes with the downside of required continual therapy.[49] The choice of bispecific antibody cannot be made based on any clinical evidence because of the lack of comparative trials. In heavily pretreated patients, bispecific antibodies impair humoral immunity, but this can be ameliorated using IV or subcutaneous immunoglobulin and antimicrobial prophylaxis.[49] Current logic supports using products with different targets sequentially.
Immunomodulatory agents
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Pomalidomide
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Pomalidomide is a third-generation immunomodulatory agent. Pomalidomide is associated with some myelosuppression and an increased incidence of thromboembolic events, as noted with lenalidomide and thalidomide (requiring thromboprophylaxis with aspirin at least), but very little peripheral neuropathy compared with other agents.
Evidence (pomalidomide):
A prospective trial (ELOQUENT-3 [NCT02654132]) included 117 patients who had relapsed or refractory disease after both lenalidomide and a proteasome inhibitor. Patients were randomly assigned to receive either EPd or Pd.[13]
Sources: ELOQUENT-3 · 13
A prospective trial (ELOQUENT-3 [NCT02654132]) included 117 patients who had relapsed or refractory disease after both lenalidomide and a proteasome inhibitor. Patients were randomly assigned to receive either EPd or Pd.[13]
With a median follow-up of 45 months, the median OS was 29.8 months (95% CI, 22.9–45.7) for patients who received EPd compared with 17.4 months (95% CI, 13.8–27.7) for patients who received Pd (HR, 0.59; 95% CI, 0.37–0.93; P = .0217).[13][Level of evidence A1]
Sources: 13 · Level of evidence A1
In a prospective trial of 559 patients with relapsed or refractory myeloma and previous treatment with lenalidomide, patients were randomly assigned to receive either pomalidomide plus bortezomib and dexamethasone or Vd.[56]
Sources: 56
In a prospective trial of 559 patients with relapsed or refractory myeloma and previous treatment with lenalidomide, patients were randomly assigned to receive either pomalidomide plus bortezomib and dexamethasone or Vd.[56]
With a median follow-up of 15.9 months, the median PFS was 11.2 months (95% CI, 9.7−13.7) in the pomalidomide combination group and 7.1 months (95% CI, 5.9−8.9) in the Vd group (HR, 0.61; 95% CI, 0.49−0.77; P < .001).[56][Level of evidence B1]
Sources: 56 · Level of evidence B1
For 302 patients with relapsed or refractory disease, Pd (40 mg weekly) was compared with a higher-dose dexamethasone regimen (40 mg daily for 4 days every 8 days).[57]
Sources: 57
For 302 patients with relapsed or refractory disease, Pd (40 mg weekly) was compared with a higher-dose dexamethasone regimen (40 mg daily for 4 days every 8 days).[57]
With a median follow-up of 10.0 months, the PFS was superior for the pomalidomide arm, at 4.0 months versus 1.9 months (HR, 0.48; 95% CI, 0.39–0.60; P < .0001)[57][Level of evidence B1]
Sources: 57 · Level of evidence B1
Lenalidomide
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Lenalidomide is a second-generation immunomodulatory agent. Lenalidomide is associated with increased incidence of thromboembolic events, as noted with pomalidomide and thalidomide (requiring thromboprophylaxis with aspirin at least), myelosuppression (more than pomalidomide), and neuropathy (less than thalidomide, but more than pomalidomide).[58-62]
A meta-analysis of 3,254 patients from seven randomized trials showed that lenalidomide was associated with an increased risk of hematologic second primary malignancies (3.1% in patients who received lenalidomide vs. 1.4% in those who did not; HR, 3.8; 95% CI, 1.15–12.62; P = .029).[63] This risk was confined to the combination of lenalidomide and melphalan (HR, 4.86; 95% CI, 2.79–8.46; P = .0001) but was not higher for lenalidomide with either cyclophosphamide or dexamethasone.[63] A retrospective review of almost 4,000 patients with relapsed or refractory disease who received lenalidomide in 11 clinical trials suggested an increased incidence of nonmelanoma skin cancers.[64]
As a result of predominant renal clearance, lenalidomide doses need to be reduced for patients with impaired renal function (creatinine clearance, 30–50: 10 mg every day; creatinine clearance, <30: 15 mg every other day; dialysis, 15 mg on day after dialysis).[65] Uncontrolled trials have added clarithromycin (500 mg twice a day) to lenalidomide and dexamethasone, with reports of increased response rates.[66] Controlled studies are required to establish the value of this approach.
Evidence (lenalidomide):
Two prospective randomized and placebo-controlled studies of 351 and 353 patients with relapsed myeloma compared lenalidomide plus high-dose dexamethasone versus high-dose dexamethasone alone.[67,68]
Two prospective randomized and placebo-controlled studies of 351 and 353 patients with relapsed myeloma compared lenalidomide plus high-dose dexamethasone versus high-dose dexamethasone alone.[67,68]
With a median follow-up of 16 to 26 months, the median OS was 29.6 months or more (not reached in one trial) versus 20.2 months to 20.6 months in the control group (HR, 0.66; 95% CI, 0.45‒0.96; P = .03 in one study [67] and P < .001 in the other study).[68][Level of evidence A1]
Sources: 67 · 68 · Level of evidence A1
A prospective randomized study of 1,623 patients with transplant-ineligible, previously untreated myeloma compared lenalidomide and dexamethasone given until disease progression with a 72-week induction regimen with melphalan, prednisone, and thalidomide (MPT) for 72 weeks.[59]
Sources: 59
A prospective randomized study of 1,623 patients with transplant-ineligible, previously untreated myeloma compared lenalidomide and dexamethasone given until disease progression with a 72-week induction regimen with melphalan, prednisone, and thalidomide (MPT) for 72 weeks.[59]
With a median follow-up of 46 months, there was improved OS for the lenalidomide group, with 4-year OS rates of 52% versus 38% (HR, 0.72; 95% CI, 0.54–0.96; P = .02).[59][Level of evidence A1]
Sources: 59 · Level of evidence A1
Thalidomide
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Thalidomide is a first-generation immunomodulatory agent that is not often used because of its sedative and constipating effects, its significant and potentially debilitating neuropathy, and its thrombogenic effect (thromboprophylaxis is required).[69,70] Very little myelosuppression is seen with this agent.
Late in the disease course, when all other options have failed, thalidomide can be employed, sometimes with durable responses.[71] By using a low dose (50 mg by mouth every day), significant sedation, constipation, and neuropathy may be avoided. Thromboprophylaxis with aspirin, warfarin, or low-molecular-weight heparin is required; the choice of therapy depends on preexisting risk factors.[62]
Evidence (thalidomide):
A meta-analysis of 1,685 previously untreated patients considered six prospective randomized trials comparing thalidomide, melphalan, and prednisone versus melphalan and prednisone alone.[72]
Sources: 72
A meta-analysis of 1,685 previously untreated patients considered six prospective randomized trials comparing thalidomide, melphalan, and prednisone versus melphalan and prednisone alone.[72]
The addition of thalidomide improved median OS from 32.7 months to 39.3 months (HR, 0.83; 95% CI, 0.73–0.94; P = .004).[72][Level of evidence A1]
Sources: 72 · Level of evidence A1
BCMA-targeting antibody-drug conjugates
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Belantamab mafodotin
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Belantamab mafodotin is an antibody-drug conjugate composed of an anti-BCMA monoclonal antibody attached to monomethyl auristatin, which inhibits microtubule formation. In 2020, the FDA approved this antibody-drug conjugate for patients with relapsed or refractory myeloma. However, this approval was withdrawn in 2023 based on findings from a prospective randomized trial in 325 patients with relapsed or refractory myeloma, which compared belantamab mafodotin with pomalidomide plus dexamethasone and showed no significant difference in median PFS.[73][Level of evidence B1] Since then, the results of several European clinical trials may revive interest in seeking FDA approval in the United States.
Sources: 73 · Level of evidence B1
Evidence (belantamab mafodotin):
A prospective randomized trial (NCT04246047) included 494 patients with relapsed or refractory myeloma. Patients received either belantamab mafodotin plus Vd or DVd.[74,75]
Sources: NCT04246047 · 74 · 75
A prospective randomized trial (NCT04246047) included 494 patients with relapsed or refractory myeloma. Patients received either belantamab mafodotin plus Vd or DVd.[74,75]
With a median follow-up of 28.2 months, the 3-year OS rate was 74% for the belantamab-Vd group and 60% for the DVd group (HR, 0.58; 95% CI, 0.43–0.79; P = .00023).[75][Level of evidence A1]
Sources: 75 · Level of evidence A1
The median PFS was 36.6 months for the belantamab mafodotin-Vd group and 13.4 months for the DVd group (HR, 0.41; 95% CI, 0.31–0.53; P < .001).[74][Level of evidence B1]
Sources: 74 · Level of evidence B1
Belantamab mafodotin is known to cause ocular toxicity (mostly in the cornea) which was noted in 79% of patients who received the drug in this trial. Monthly corneal examinations allowed for dose modification, and 98% of patients regained normal vision from 20/50 or worse.
A prospective randomized trial (NCT04484623) included 302 patients with relapsed or refractory myeloma. Patients received either belantamab mafodotin plus Pd (BPd) or PVd (pomalidomide, bortezomib, and dexamethasone).[76]
Sources: NCT04484623 · 76
A prospective randomized trial (NCT04484623) included 302 patients with relapsed or refractory myeloma. Patients received either belantamab mafodotin plus Pd (BPd) or PVd (pomalidomide, bortezomib, and dexamethasone).[76]
With a median follow-up of 21.8 months, the 1-year PFS rate was 71% for the BPd group and 51% for the PVd group (HR, 0.52; 95% CI, 0.37–0.73; P < .001).[76][Level of evidence B1]
Sources: 76 · Level of evidence B1
Belantamab mafodotin is known to cause ocular toxicity (usually in the cornea). Grade 3 or 4 ocular toxicity occurred in 43% of patients who received the drug in this trial (all-grades toxicity occurred in 89% of patients). Monthly corneal examinations allowed for dose modification, and 9% of patients in the BPd group required early treatment discontinuation.
Summary: The use of BCMA-targeted therapy in the second- or third-line of therapy appears better than the usual standard of care. FDA approval may occur after review of these European trials. The use of belantamab mafodotin may affect the subsequent efficacy of other BCMA-directed therapies that have already been approved by the FDA, including the CAR T-cell therapies, cilta-cel and ide-cel, and the bispecific BCMA T-cell enhancers, teclistamab and elranatamab. Clinical trials must establish the correct sequencing of BCMA-directed therapies. In the meantime, belantamab mafodotin has not been approved by the FDA.
Chemotherapy (cytotoxic agents)
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Regimens:
Pegylated liposomal doxorubicin (in a modified VAD regimen) [83,84] or combined with bortezomib and dexamethasone.[85]
Evidence (chemotherapy):
A meta-analysis of prospective randomized trials compared melphalan and prednisone with combinations of other cytotoxic agents. No differences were noted in PFS or OS.[78][Level of evidence A1]
Sources: 78 · Level of evidence A1
The VAD regimen has shown activity in previously untreated patients and in relapsed patients, with response rates ranging from 60% to 80%.[79,80][Level of evidence C3] Because of logistics problems delivering a 96-hour infusion of doxorubicin, substitution with pegylated liposomal doxorubicin provides comparable response rates.[83,84]
Sources: 79 · 80 · Level of evidence C3 · 83 · 84
Chemotherapy alone has been used to obtain a clinical remission after exhausting most of the new regimens, allowing improvement in performance status that may permit subsequent use of clinical trials investigating alternative therapies.
Selinexor
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Selinexor is a selective inhibitor of nuclear export compounds that blocks exportin 1 (which activates tumor suppressor proteins), inhibits nuclear factor κB, and reduces oncoprotein mRNA translation.
Selinexor (evidence):
A prospective randomized trial included 402 patients with relapsed or refractory disease. Patients received either selinexor plus bortezomib and dexamethasone (SVd) or Vd.[86]
Sources: 86
A prospective randomized trial included 402 patients with relapsed or refractory disease. Patients received either selinexor plus bortezomib and dexamethasone (SVd) or Vd.[86]
With a median follow-up of 13.2 months (SVd) or 16.5 months (Vd), the median PFS was 13.9 months (95% CI, 11.7–not evaluable) for patients who received SVd and 9.5 months (95% CI, 8.1–10.8) for patients who received Vd (HR, 0.70; 95% CI, 0.53–0.93; P = .0075).[86][Level of evidence B1]
Sources: 86 · Level of evidence B1
Patients who received the selinexor combination had more thrombocytopenia (39% vs. 17%) and fatigue (13% vs. 1%).
In a phase IIB multicenter study, 122 patients with multiply resistant myeloma refractory to a proteasome inhibitor, an immunomodulatory agent, and daratumumab received oral selinexor and dexamethasone.[87] High-risk cytogenetics were present in 53% of patients. Patients had received a median of seven previous regimens.
Sources: 87
In a phase IIB multicenter study, 122 patients with multiply resistant myeloma refractory to a proteasome inhibitor, an immunomodulatory agent, and daratumumab received oral selinexor and dexamethasone.[87] High-risk cytogenetics were present in 53% of patients. Patients had received a median of seven previous regimens.
A partial response or better was observed in 26% of patients (95% CI, 19%−35%), with a median duration of response of 4.4 months. The median PFS was 3.7 months; median OS was 8.6 months.[87][Level of evidence C3]
Sources: 87 · Level of evidence C3
In a phase II study of 42 patients with relapsed or refractory disease, patients received SVd.[88]
Sources: 88
In a phase II study of 42 patients with relapsed or refractory disease, patients received SVd.[88]
A partial response or better was observed in 63% of patients, with a median PFS of 9.0 months.[88][Level of evidence C3]
Sources: 88 · Level of evidence C3
Selinexor has significant side effects, including nausea, vomiting, fatigue, diarrhea, weight loss, poor appetite, and cytopenias. A descriptive retrospective study of 437 patients enrolled in clinical trials focused on aggressive medical support for these side effects.[89]
Sources: 89
Venetoclax
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Venetoclax is a selective BCL-2 inhibitor that induces apoptosis in myeloma cells, particularly in those with t(11;14), which expresses high levels of bcl2.
Evidence (venetoclax):
In a phase I study of 66 heavily pretreated patients with relapsed or refractory myeloma, 30 patients harbored a t(11;14) translocation.[90]
Sources: 90
In a phase I study of 66 heavily pretreated patients with relapsed or refractory myeloma, 30 patients harbored a t(11;14) translocation.[90]
Among all 66 patients, the overall response rate was 21%, and 15% of patients achieved very good partial response or better. For those with t(11;14), the overall response rate was 40%, with 27% achieving a very good partial response or better.[90][Level of evidence C3]
Sources: 90 · Level of evidence C3
In a prospective trial (BELLINI [NCT02755597]), 291 patients with relapsed or refractory myeloma were randomly assigned to receive venetoclax plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone.[91]
In a prospective trial (BELLINI [NCT02755597]), 291 patients with relapsed or refractory myeloma were randomly assigned to receive venetoclax plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone.[91]
With a median follow-up of 18.7 months, the median PFS was 22.4 months for patients on the venetoclax arm versus 11.5 months for patients on the placebo arm (HR, 0.63; 95% CI, 0.44–0.90; P = .01).
OS favored the placebo arm because of treatment-related sepsis (HR, 2.03; 95% CI, 1.04–3.95; P = .034).[91][Level of evidence A1]
Sources: 91 · Level of evidence A1
A prespecified analysis of 35 patients with t(11;14) translocation (20 patients who received venetoclax and 15 patients who received placebo) resulted in the median PFS not being reached for patients on the venetoclax arm versus 9.5 months for patients on the placebo arm (HR, 0.11; 95% CI, 0.02–0.56; P = .004).[91][Level of evidence B1]
Sources: 91 · Level of evidence B1
BRAF/MEK inhibitors
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Although activating BRAF variants are rarely found in patients with newly diagnosed myeloma, these variants appear in multiple-relapsing disease. Twelve such patients with a BRAF V600E variant who received encorafenib and binimetinib had an overall response rate of 83.3%, a median PFS of 5.6 months, and an OS rate of 55% at 24 months.[92][Level of evidence C3]
Sources: 92 · Level of evidence C3
Corticosteroids
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Dexamethasone dosage has been evaluated in two prospective randomized trials.
A prospective randomized study (ECOG-E4A03) of 445 previously untreated patients with myeloma compared lenalidomide and high-dose dexamethasone (40 mg on days 1–4, 9–12, and 17–20, every 28 days) with lenalidomide and low-dose dexamethasone (40 mg on days 1, 8, 15, and 22, every 28 days).[58]
Sources: ECOG-E4A03 · 58
A prospective randomized study (ECOG-E4A03) of 445 previously untreated patients with myeloma compared lenalidomide and high-dose dexamethasone (40 mg on days 1–4, 9–12, and 17–20, every 28 days) with lenalidomide and low-dose dexamethasone (40 mg on days 1, 8, 15, and 22, every 28 days).[58]
With a median follow-up of 36 months, the 2-year OS rate favored the low-dose dexamethasone arm (87% vs. 75%; P = .006), despite no difference in PFS.[58][Level of evidence A1]
Sources: 58 · Level of evidence A1
The increased deaths on the high-dose dexamethasone arm were attributed to cardiopulmonary toxicity.
Deep venous thromboses (DVTs) were also more frequent in the high-dose arm (25% vs. 9%). Patients in the low-dose dexamethasone arm with lenalidomide experienced less than 5% DVT with aspirin alone.
A prospective randomized trial of melphalan and prednisone versus melphalan and high-dose dexamethasone showed no difference in PFS or OS, but there was an increase in infection in the high-dose dexamethasone arm.[93]
Sources: 93
A retrospective review of 541 patients in pooled myeloma studies from the Southwest Oncology Group found frequent dosage reductions of dexamethasone because of toxicity. These dose reductions did not appear to impact PFS or OS.[94][Level of evidence C3]
Sources: 94 · Level of evidence C3
Summary: Although prospective randomized trials are needed to clarify the role of corticosteroids or their dose, it is doubtful that those studies will ever be performed.
Based on these trials, all ongoing trials and regimens use the low-dose dexamethasone schedule in combination with other therapeutic agents: 40 mg dexamethasone (oral or IV) weekly in fit patients, or 20 mg (oral or IV) in less-fit patients at higher risk for complications.
Certain factors affect prognosis (chance of recovery) and treatment options.
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: November 17, 2023. Captured 2026-09-09.
The prognosis depends on the following:
Sources: prognosis
The type of plasma cell neoplasm.
The stage of the disease.
Sources: stage
Whether a certain immunoglobulin (antibody) is present.
Whether there are certain genetic changes.
Sources: genetic
Whether the kidney is damaged.
Whether the cancer responds to initial treatment or recurs (comes back).
Sources: responds · initial treatment · recurs
Treatment options depend on the following:
The type of plasma cell neoplasm.
The age and general health of the patient.
Whether there are signs, symptoms, or health problems, such as kidney failure or infection, related to the disease.
Sources: kidney failure
Whether the cancer responds to initial treatment or recurs (comes back).
Plasma cell neoplasms may not respond to treatment or may come back after treatment.
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: November 17, 2023. Captured 2026-09-09.
Plasma cell neoplasms are called refractory when the number of plasma cells keeps going up even though treatment is given. Plasma cell neoplasms are called relapsed when they have come back after treatment.
Sources: neoplasms · refractory · relapsed
Treatment Option Overview
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: November 17, 2023. Captured 2026-09-09.
Key Points
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: November 17, 2023. Captured 2026-09-09.
There are different types of treatment for patients with plasma cell neoplasms.
The following types of treatment are used:
The following types of treatment are used:
Chemotherapy
Other drug therapy
Targeted therapy
High-dose chemotherapy with stem cell transplant
Immunotherapy
Radiation therapy
Surgery
Watchful waiting
New types of treatment are being tested in clinical trials.
New types of treatment are being tested in clinical trials.
New combinations of therapies
Treatment for plasma cell neoplasms may cause side effects.
Supportive care is given to lessen the problems caused by the disease or its treatment.
Patients may want to think about taking part in a clinical trial.
Patients can enter clinical trials before, during, or after starting their cancer treatment.
Follow-up tests may be needed.
There are different types of treatment for patients with plasma cell neoplasms.
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: November 17, 2023. Captured 2026-09-09.
Different types of treatments are available for patients with plasma cell neoplasms. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.
Sources: plasma cell · neoplasms · standard · clinical trials · research study · cancer
The following types of treatment are used:
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: November 17, 2023. Captured 2026-09-09.
Chemotherapy
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: November 17, 2023. Captured 2026-09-09.
Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy).
Sources: Chemotherapy · drugs · cells · injected · vein · systemic chemotherapy
See Drugs Approved for Multiple Myeloma and Other Plasma Cell Neoplasms.
Sources: Drugs Approved for Multiple Myeloma and Other Plasma Cell Neoplasms
Other drug therapy
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: November 17, 2023. Captured 2026-09-09.
Corticosteroids are steroids that have antitumor effects in multiple myeloma.
Sources: Corticosteroids · steroids · antitumor · multiple myeloma
Targeted therapy
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: November 17, 2023. Captured 2026-09-09.
Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Several types of targeted therapy may be used to treat multiple myeloma and other plasma cell neoplasms. There are different types of targeted therapy:
Sources: Targeted therapy
Proteasome inhibitor therapy: This treatment blocks the action of proteasomes in cancer cells. A proteasome is a protein that removes other proteins no longer needed by the cell. When the proteins are not removed from the cell, they build up and may cause the cancer cell to die. Bortezomib, carfilzomib, and ixazomib are proteasome inhibitors used in the treatment of multiple myeloma and other plasma cell neoplasms.
Sources: Proteasome inhibitor · therapy · protein · Bortezomib · carfilzomib · ixazomib
Monoclonal antibody therapy: Monoclonal antibodies are immune system proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these antibodies can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells. Daratumumab and elotuzumab are monoclonal antibodies used in the treatment of multiple myeloma and other plasma cell neoplasms. Denosumab is a monoclonal antibody used to slow bone loss and reduce bone pain in patients with multiple myeloma.
Sources: Monoclonal antibody · immune system · antibodies · infusion · toxins · radioactive · Daratumumab · elotuzumab · Denosumab
BCL2 inhibitor therapy: This treatment blocks a protein called BCL2. Blocking this protein may help kill cancer cells and may make them more sensitive to anticancer drugs. Venetoclax is a BCL2 inhibitor being studied in the treatment of relapsed or refractory multiple myeloma.
Sources: BCL2 · Venetoclax · relapsed · refractory
See Drugs Approved for Multiple Myeloma and Other Plasma Cell Neoplasms.
Sources: Drugs Approved for Multiple Myeloma and Other Plasma Cell Neoplasms
High-dose chemotherapy with stem cell transplant
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: November 17, 2023. Captured 2026-09-09.
High doses of chemotherapy are given to kill cancer cells. Healthy cells, including blood-forming cells, are also destroyed by the cancer treatment. Stem cell transplant is a treatment to replace the blood-forming cells. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient (autologous) or a donor (allogeneic) and are frozen and stored. After the patient completes chemotherapy, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the body's blood cells.
Sources: doses · blood · Stem cell transplant · Stem cells · bone marrow · autologous · donor · allogeneic
Immunotherapy
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: November 17, 2023. Captured 2026-09-09.
Immunotherapy is a treatment that uses the patient's immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body's natural defenses against cancer. This cancer treatment is a type of biologic therapy.
Sources: Immunotherapy · biologic therapy
Immunomodulator therapy: Thalidomide, lenalidomide, and pomalidomide are immunomodulators used to treat multiple myeloma and other plasma cell neoplasms.
Sources: Thalidomide · lenalidomide · pomalidomide
CAR T-cell therapy: This treatment changes the patient's T cells (a type of immune system cell) so they will attack certain proteins on the surface of cancer cells. T cells are taken from the patient and special receptors are added to their surface in the laboratory. The changed cells are called chimeric antigen receptor (CAR) T cells. The CAR T cells are grown in the laboratory and given to the patient by infusion. The CAR T cells multiply in the patient's blood and attack cancer cells. CAR T-cell therapy is being studied in the treatment of multiple myeloma that has recurred (come back).
Sources: CAR T-cell therapy · T cells · receptors · chimeric antigen receptor · recurred
See Drugs Approved for Multiple Myeloma and Other Plasma Cell Neoplasms.
Sources: Drugs Approved for Multiple Myeloma and Other Plasma Cell Neoplasms
Radiation therapy
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: November 17, 2023. Captured 2026-09-09.
Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer.
Sources: x-rays · radiation · External radiation therapy
Surgery
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: November 17, 2023. Captured 2026-09-09.
Surgery to remove the tumor may be done. After the doctor removes all the cancer that can be seen at the time of the surgery, some patients may be given radiation therapy after surgery to kill any cancer cells that are left. Treatment given after the surgery, to lower the risk that the cancer will come back, is called adjuvant therapy.
Sources: Surgery · adjuvant therapy
Watchful waiting
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: November 17, 2023. Captured 2026-09-09.
Watchful waiting is closely monitoring a patient’s condition without giving any treatment until signs or symptoms appear or change.
Sources: Watchful waiting · monitoring · condition · signs
New types of treatment are being tested in clinical trials.
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: November 17, 2023. Captured 2026-09-09.
This summary section describes treatments that are being studied in clinical trials. It may not mention every new treatment being studied. Information about clinical trials is available from the NCI website.
Sources: NCI website
New combinations of therapies
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: November 17, 2023. Captured 2026-09-09.
Clinical trials are studying different combinations of immunotherapy, chemotherapy, steroid therapy, and drugs. New treatment regimens using selinexor are also being studied.
Sources: steroid therapy · regimens · selinexor
Treatment for plasma cell neoplasms may cause side effects.
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: November 17, 2023. Captured 2026-09-09.
For information about side effects caused by treatment for cancer, visit our Side Effects page.
Sources: side effects · Side Effects
Supportive care is given to lessen the problems caused by the disease or its treatment.
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: November 17, 2023. Captured 2026-09-09.
This therapy controls problems or side effects caused by the disease or its treatment, and improves quality of life. Supportive care is given to treat problems caused by multiple myeloma and other plasma cell neoplasms.
Sources: side effects · Supportive care
Supportive care may include the following:
Plasmapheresis: If the blood becomes thick with extra antibody proteins and interferes with circulation, plasmapheresis is done to remove extra plasma and antibody proteins from the blood. In this procedure blood is removed from the patient and sent through a machine that separates the plasma (the liquid part of the blood) from the blood cells. The patient's plasma contains the unneeded antibodies and is not returned to the patient. The normal blood cells are returned to the bloodstream along with donated plasma or a plasma replacement. Plasmapheresis does not keep new antibodies from forming.
Sources: Plasmapheresis · circulation · plasma
Induction therapy with stem cell transplant: If amyloidosis occurs, treatment may include induction therapy followed by stem cell transplant using the patient's own stem cells.
Sources: Induction therapy · amyloidosis
Immunotherapy: Immunotherapy with thalidomide, lenalidomide, or pomalidomide is given to treat amyloidosis.
Targeted therapy: Targeted therapy with proteasome inhibitors is given to decrease how much immunoglobulin M is in the blood and treat amyloidosis. Targeted therapy with daratumumab is given with or without other drugs to treat amyloidosis. Targeted therapy with a monoclonal antibody is given to slow bone loss and reduce bone pain.
Sources: immunoglobulin
Radiation therapy: Radiation therapy is given for bone lesions of the spine.
Chemotherapy: Chemotherapy is given to reduce back pain from osteoporosis or compression fractures of the spine.
Sources: osteoporosis · compression fractures
Bisphosphonate therapy: Bisphosphonate therapy is given to slow bone loss and reduce bone pain. For more information on bisphosphonates and problems related to their use, see Oral Complications of Cancer Therapies.
Sources: Bisphosphonate · Oral Complications of Cancer Therapies
Patients may want to think about taking part in a clinical trial.
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: November 17, 2023. Captured 2026-09-09.
For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.
Sources: clinical trial · standard treatment
Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.
Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.
Patients can enter clinical trials before, during, or after starting their cancer treatment.
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: November 17, 2023. Captured 2026-09-09.
Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.
Sources: side effects
Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trials search · ClinicalTrials.gov
Follow-up tests may be needed.
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: November 17, 2023. Captured 2026-09-09.
As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.
Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).
Treatment of Monoclonal Gammopathy of Undetermined Significance
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: November 17, 2023. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of monoclonal gammopathy of undetermined significance (MGUS) is usually watchful waiting. Regular blood tests to check the level of M protein in the blood and physical exams to check for signs or symptoms of cancer will be done.
Sources: monoclonal gammopathy of undetermined significance · watchful waiting · blood tests · M protein · blood · physical exams · signs · symptoms · cancer
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Treatment of Isolated Plasmacytoma of Bone
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: November 17, 2023. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of isolated plasmacytoma of bone is usually radiation therapy to the bone lesion.
Sources: plasmacytoma · radiation therapy · lesion
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Triangle